###begin article-title 0
###xml 123 128 <span type="species:ncbi:9606">human</span>
alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy
###end article-title 0
###begin p 1
###xml 806 810 761 765 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add2</italic>
###xml 1155 1159 1102 1106 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add1</italic>
###xml 1307 1313 1251 1257 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">rs4984</italic>
###xml 1378 1384 1318 1324 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">rs4961</italic>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 509 513 <span type="species:ncbi:10116">rats</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 586 590 <span type="species:ncbi:10090">mice</span>
###xml 818 822 <span type="species:ncbi:10116">rats</span>
###xml 1171 1179 <span type="species:ncbi:9606">patients</span>
Adducins are cytoskeletal actin-binding proteins (alpha, beta, gamma) that function as heterodimers and heterotetramers and are encoded by distinct genes. Experimental and clinical evidence implicates alpha- and beta-adducin variants in hypertension and renal dysfunction. Here, we have addressed the role of alpha- and beta-adducin on glomerular function and disease using beta-adducin null mice, congenic substrains for alpha- and beta-adducin from the Milan hypertensive (MHS) and Milan normotensive (MNS) rats and patients with IgA nephropathy. Targeted deletion of beta-adducin in mice reduced urinary protein excretion, preceded by an increase of podocyte protein expression (phospho-nephrin, synaptopodin, alpha-actinin, ZO-1, Fyn). The introgression of polymorphic MHS beta-adducin locus into MNS (Add2, 529R) rats was associated with an early reduction of podocyte protein expression (nephrin, synaptopodin, alpha-actinin, ZO-1, podocin, Fyn), followed by severe glomerular and interstitial lesions and increased urinary protein excretion. These alterations were markedly attenuated when the polymorphic MHS alpha-adducin locus was also present (Add1, 316Y). In patients with IgA nephropathy, the rate of decline of renal function over time was associated to polymorphic beta-adducin (ADD2, 1797T, rs4984) with a significant interaction with alpha-adducin (ADD1, 460W, rs4961). These findings suggest that adducin genetic variants participate in the development of glomerular lesions by modulating the expression of specific podocyte proteins.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
The online version of this article (doi:10.1007/s00109-009-0549-x) contains supplementary material, which is available to authorized users.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 340 341 340 341 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 570 571 570 571 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 572 573 572 573 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
Renal failure, triggered by a variety of factors, is a major and costly health care burden. After an apparently similar initial glomerular injury, large individual variations occur in the rate of progression toward renal failure as well as in the magnitude of urinary protein excretion, which is the major predictor of disease progression [1]. Polymorphisms within genes encoding a few proteins associated with the podocyte actin cytoskeleton are responsible for glomerular proteinuria and progression toward failure in some monogenic and polygenic glomerular diseases [2-5].
###end p 6
###begin p 7
###xml 289 290 278 279 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 292 293 281 282 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 411 412 400 401 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 413 415 402 404 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 394 398 <span type="species:ncbi:10116">rats</span>
###xml 403 409 <span type="species:ncbi:9606">humans</span>
Adducin is a heterodimeric protein composed by alpha, beta, and gamma subunits, encoded by distinct genes, that regulate actin polymerization and bundling as well as basic cellular functions involving the actin cytoskeleton, such as ion transport, cell motility, morphology, and adhesion [6, 7]. Genetic variations within adducin genes have been shown to be involved in primary hypertension in rats and humans [8-11].
###end p 7
###begin p 8
###xml 103 104 103 104 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 322 324 315 317 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 325 327 318 320 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 377 379 370 372 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 470 474 452 456 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add1</italic>
###xml 497 501 476 480 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add2</italic>
###xml 511 512 490 491 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 514 515 493 494 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 517 519 496 498 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 561 567 536 542 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">rs4961</italic>
###xml 579 585 554 560 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">rs4963</italic>
###xml 615 621 587 593 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">rs4984</italic>
###xml 624 625 596 597 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 627 629 599 601 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 525 531 <span type="species:ncbi:9606">humans</span>
###xml 1020 1026 <span type="species:ncbi:9606">humans</span>
###xml 1221 1226 <span type="species:ncbi:9606">human</span>
###xml 1292 1296 <span type="species:ncbi:10090">mice</span>
###xml 1513 1516 <span type="species:ncbi:10116">rat</span>
###xml 1574 1577 <span type="species:ncbi:10116">rat</span>
###xml 1812 1820 <span type="species:ncbi:9606">patients</span>
To date, no link has been suggested between adducin polymorphisms and podocyte or glomerular function [2]. Indeed, alpha- and beta-adducin polymorphisms have been variously found to be associated with progression of renal failure in the presence of overt nephropathy or with decay of renal function in population studies [12-16], although the results have not been consistent [17]. Polymorphisms within the alpha- and beta-adducin genes occur in rodents (alpha-adducin, Add1, F316Y; beta-adducin, Add2, Q529R) [7, 8, 10] and humans (alpha-adducin, ADD1, G460W, rs4961 and S586C, rs4963; beta-adducin, ADD2, C1797T, rs4984) [9, 10], although at different positions, therefore different outcomes might be expected between species as function of these genetic variants. These observations call for a set of experimental and clinical approaches aimed at establishing whether these genetic variations within the alpha- and beta-adducin genes are associated with changes in glomerular or podocyte function both in rodents and humans. This aim was pursued with the following three approaches to evaluate the impact of adducin variations across different contexts and to test to what extent rodent data may help in understanding human data: (1) the effect of the knockout of the beta-adducin gene in mice on blood pressure, urinary protein excretion, and podocyte protein expression; (2) the effect of the introgression of a DNA segment, harboring the polymorphic alpha- and beta-adducin loci from the Milan hypertensive rat strain (MHS) into the normotensive strain (MNS; congenic rat substrains) on blood pressure, urinary protein excretion, glomerular morphology, and function and podocyte protein expression; and (3) the association of alpha- and beta-adducin genotypes with the rate of decline of renal function in patients with IgA nephropathy.
###end p 8
###begin p 9
###xml 272 274 272 274 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 361 363 361 363 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
IgA nephropathy was selected as disease model for several reasons, among which: (1) it is the commonest glomerulonephritis worldwide, (2) its outcome is extremely variable, spanning from decades of normal renal function to fast progression toward end stage renal disease [18], and (3) few clinical features have been detected as predictors of progression rate [19].
###end p 9
###begin title 10
Materials and methods
###end title 10
###begin title 11
Animal models
###end title 11
###begin p 12
###xml 595 599 582 586 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add2</italic>
###xml 683 689 667 673 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">tm1Llp</sup>
###xml 727 729 711 713 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 834 835 815 816 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 581 860 571 841 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="13">&#946;-Adducin (<italic>Add2</italic>) null mouse model: &#946;-adducin knockout mice (official strain designation 129-Add2<sup>tm1Llp</sup>/Llp) have been previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. Wild-type 129/Sv mice, carrying the same &#946;-adducin polymorphism (Q529R) described in the MHS rats [<xref ref-type="bibr" rid="CR7">7</xref>], were used as controls.</p>
###xml 581 860 571 841 <list-item xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="13">&#946;-Adducin (<italic>Add2</italic>) null mouse model: &#946;-adducin knockout mice (official strain designation 129-Add2<sup>tm1Llp</sup>/Llp) have been previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. Wild-type 129/Sv mice, carrying the same &#946;-adducin polymorphism (Q529R) described in the MHS rats [<xref ref-type="bibr" rid="CR7">7</xref>], were used as controls.</p></list-item>
###xml 1154 1156 1135 1137 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1361 1365 1338 1342 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add1</italic>
###xml 1445 1449 1419 1423 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add2</italic>
###xml 1495 1497 1469 1471 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 860 1499 841 1473 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="14">Selection of congenic rat substrains from MHS and MNS parental strains: MHS, hypertensive, and MNS, normotensive, parental rats were derived from the internal stock colony (Prassis sigma-tau). Congenic rat strains were obtained from MHS hypertensive and MNS normotensive strains, as described [<xref ref-type="bibr" rid="CR21">21</xref>]. The donor strain was the MHS and the receiving genetic background was the MNS. The integrated physical and linkage map of the congenic segment indicated that the reciprocal congenics for &#945;-adducin (<italic>Add1</italic>) contained a minimum/maximum of 1.0/8.8&#160;Mb (6.6&#160;cM) and that for &#946;-adducin (<italic>Add2</italic>) a minimum/maximum of 1.0/26.4&#160;Mb (13.5&#160;cM) [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
###xml 860 1499 841 1473 <list-item xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="14">Selection of congenic rat substrains from MHS and MNS parental strains: MHS, hypertensive, and MNS, normotensive, parental rats were derived from the internal stock colony (Prassis sigma-tau). Congenic rat strains were obtained from MHS hypertensive and MNS normotensive strains, as described [<xref ref-type="bibr" rid="CR21">21</xref>]. The donor strain was the MHS and the receiving genetic background was the MNS. The integrated physical and linkage map of the congenic segment indicated that the reciprocal congenics for &#945;-adducin (<italic>Add1</italic>) contained a minimum/maximum of 1.0/8.8&#160;Mb (6.6&#160;cM) and that for &#946;-adducin (<italic>Add2</italic>) a minimum/maximum of 1.0/26.4&#160;Mb (13.5&#160;cM) [<xref ref-type="bibr" rid="CR21">21</xref>].</p></list-item>
###xml 581 1499 571 1473 <list xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="13">&#946;-Adducin (<italic>Add2</italic>) null mouse model: &#946;-adducin knockout mice (official strain designation 129-Add2<sup>tm1Llp</sup>/Llp) have been previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. Wild-type 129/Sv mice, carrying the same &#946;-adducin polymorphism (Q529R) described in the MHS rats [<xref ref-type="bibr" rid="CR7">7</xref>], were used as controls.</p></list-item><list-item><p textid="14">Selection of congenic rat substrains from MHS and MNS parental strains: MHS, hypertensive, and MNS, normotensive, parental rats were derived from the internal stock colony (Prassis sigma-tau). Congenic rat strains were obtained from MHS hypertensive and MNS normotensive strains, as described [<xref ref-type="bibr" rid="CR21">21</xref>]. The donor strain was the MHS and the receiving genetic background was the MNS. The integrated physical and linkage map of the congenic segment indicated that the reciprocal congenics for &#945;-adducin (<italic>Add1</italic>) contained a minimum/maximum of 1.0/8.8&#160;Mb (6.6&#160;cM) and that for &#946;-adducin (<italic>Add2</italic>) a minimum/maximum of 1.0/26.4&#160;Mb (13.5&#160;cM) [<xref ref-type="bibr" rid="CR21">21</xref>].</p></list-item></list>
###xml 606 611 <span type="species:ncbi:10090">mouse</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 828 832 <span type="species:ncbi:10116">rats</span>
###xml 882 885 <span type="species:ncbi:10116">rat</span>
###xml 983 987 <span type="species:ncbi:10116">rats</span>
###xml 1062 1065 <span type="species:ncbi:10116">rat</span>
All procedures for animal care were carried out in accordance with Prassis Institutional Guidelines. The care and husbandry of animals complied with the European Directives no 86/609 and with the Italian Law (DL116, January 27, 1992). The authorization for animal use in Prassis Laboratories was obtained from the Italian Health Authority. Animals had free access to the chow (standard diet, Altromin, Rieper, Italy) and to tap water and were maintained under controlled conditions of air temperature (22 +/- 2degreesC), relative humidity (50 +/- 15%), and day/night cycle (12 h): beta-Adducin (Add2) null mouse model: beta-adducin knockout mice (official strain designation 129-Add2tm1Llp/Llp) have been previously described [20]. Wild-type 129/Sv mice, carrying the same beta-adducin polymorphism (Q529R) described in the MHS rats [7], were used as controls.Selection of congenic rat substrains from MHS and MNS parental strains: MHS, hypertensive, and MNS, normotensive, parental rats were derived from the internal stock colony (Prassis sigma-tau). Congenic rat strains were obtained from MHS hypertensive and MNS normotensive strains, as described [21]. The donor strain was the MHS and the receiving genetic background was the MNS. The integrated physical and linkage map of the congenic segment indicated that the reciprocal congenics for alpha-adducin (Add1) contained a minimum/maximum of 1.0/8.8 Mb (6.6 cM) and that for beta-adducin (Add2) a minimum/maximum of 1.0/26.4 Mb (13.5 cM) [21].
###end p 12
###begin p 13
###xml 14 18 11 15 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add2</italic>
###xml 102 108 96 102 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">tm1Llp</sup>
###xml 146 148 140 142 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 253 254 244 245 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10116">rats</span>
beta-Adducin (Add2) null mouse model: beta-adducin knockout mice (official strain designation 129-Add2tm1Llp/Llp) have been previously described [20]. Wild-type 129/Sv mice, carrying the same beta-adducin polymorphism (Q529R) described in the MHS rats [7], were used as controls.
###end p 13
###begin p 14
###xml 294 296 294 296 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 501 505 497 501 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add1</italic>
###xml 585 589 578 582 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Add2</italic>
###xml 635 637 628 630 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 22 25 <span type="species:ncbi:10116">rat</span>
###xml 123 127 <span type="species:ncbi:10116">rats</span>
###xml 202 205 <span type="species:ncbi:10116">rat</span>
Selection of congenic rat substrains from MHS and MNS parental strains: MHS, hypertensive, and MNS, normotensive, parental rats were derived from the internal stock colony (Prassis sigma-tau). Congenic rat strains were obtained from MHS hypertensive and MNS normotensive strains, as described [21]. The donor strain was the MHS and the receiving genetic background was the MNS. The integrated physical and linkage map of the congenic segment indicated that the reciprocal congenics for alpha-adducin (Add1) contained a minimum/maximum of 1.0/8.8 Mb (6.6 cM) and that for beta-adducin (Add2) a minimum/maximum of 1.0/26.4 Mb (13.5 cM) [21].
###end p 14
###begin p 15
###xml 72 76 <span type="species:ncbi:10116">rats</span>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Systolic blood pressure (SBP) and heart rate were recorded in conscious rats (from 2 to 6 months of age) and in mice (at 8 and 11 months) by an indirect tail-cuff plethysmographic method (BP recorder, U. Basile, Varese, Italy).
###end p 15
###begin title 16
Biochemical assays for urinary parameter measurements
###end title 16
###begin p 17
###xml 482 483 482 483 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 489 490 489 490 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 51 55 <span type="species:ncbi:10116">rats</span>
###xml 95 99 <span type="species:ncbi:10116">Rats</span>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">Mice</span>
Urinary parameters were measured in conscious male rats at 1.5, 3, 6, 8, and 11 months of age. Rats were housed in individual metabolic cages and had free access to water and food. Urinary parameters were also measured in conscious wild-type and knockout mice at 8 and 11 months of age. Mice received a bolus of 1 ml physiological solution by gavages, and urine was collected over a period of 6 h. Urine samples were analyzed for the following parameters: volume, pH, osmolality, Na+ and K+ concentrations (IL 943 photometer), total protein excretion (total protein Kit, Sentinel Diagnostics, Milan, Italy), and creatinine (colorimetric Kit, Sentinel Diagnostics).
###end p 17
###begin title 18
Histological and immunohistochemical studies
###end title 18
###begin p 19
###xml 200 202 199 201 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
Renal tissue samples for light microscopy were fixed in 4% buffered paraformaldehyde and embedded in paraffin. Routine staining was performed on 2-mum-thick sections according to standard techniques [22].
###end p 19
###begin p 20
For immunofluorescence and immunohistochemistry, unfixed renal tissue was embedded in OCT compound (Miles Scientific, Naperville, IL, USA), snap-frozen in a mixture of isopentane and dry-ice, and stored at -80degreesC. Five-micrometer sections were placed on slides and fixed in cold acetone. In indirect immunofluorescence, the bound primary antibody was detected by Alexa Fluor 488 antirabbit or antimouse IgG (Invitrogen). For immunohistochemistry, after blocking endogenous biotin and endogenous peroxidase, the primary antibody was followed by an appropriate biotinylated secondary antibody and peroxidase-labeled streptavidin (both from Invitrogen), finally developed by diaminobenzidine (Sigma). Slides were mounted either with Vecta-shield aqueous mounting medium (Vector Laboratories, DBA Italia SRL) or with Bio Mount (Bio Optica, Milan, Italy).
###end p 20
###begin title 21
Glomeruli and podocyte isolation
###end title 21
###begin p 22
###xml 182 183 176 177 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 41 45 <span type="species:ncbi:10116">rats</span>
Kidneys were taken from 7- to 10-day-old rats. Glomeruli were isolated by sieving then seeded in culture flasks precoated with collagen type IV (Sigma-Aldrich) at 37degreesC in 5% CO2 atmosphere. On days 4 to 5, podocyte growth started, and by day 8, glomeruli were detached using trypsin-EDTA and filtered through the 36-mum mesh to eliminate glomeruli. Second passage podocytes, >90% pure as judged by light microscopy, were seeded on flasks and chamber slides. Cell characterization was performed by immunofluorescence, using markers for podocytes (nephrin, podocin), epithelial (cytokeratin), smooth muscle (alpha-SMA), and endothelial cells (CD31).
###end p 22
###begin title 23
Western blotting
###end title 23
###begin p 24
Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted and overnight incubated at 4degreesC with specific primary antibodies, followed by 1 h incubation with fluorescent secondary antibodies (Alexa Fluor), then analyzed and quantified by Odyssey Infrared Imaging Detection System (LI-COR Biosciences). Antibodies were anti-alpha- and anti-beta-adducin (raised by S. Salardi in Prassis); anti-nephrin, anti-Fyn (Santa Cruz); anti-phospho-nephrin (kindly provided by Larry Holzman); anti-vimentin, anti-ZO-1, anti-alpha-SMA (Invitrogen); anti-synaptopodin (Progen Biotechnik); anti-alpha-actinin (Calbiochem); anti-podocin, anti-actin (Sigma-Aldrich); and anti-cytokeratin, anti-CD31 (Abcam).
###end p 24
###begin title 25
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human studies
###end title 25
###begin p 26
###xml 39 51 <span type="species:ncbi:9606">participants</span>
Informed consent was obtained from all participants in the study, which was approved by the Ethical Committee of the San Raffaele Hospital, Milan, Italy.
###end p 26
###begin p 27
###xml 876 878 876 878 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1075 1077 1075 1077 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1243 1245 1243 1245 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1250 1252 1250 1252 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1645 1647 1645 1647 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 353 360 <span type="species:ncbi:9606">patient</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
###xml 1159 1166 <span type="species:ncbi:9606">patient</span>
Three hundred seventy-three patients, with biopsy proven primary IgA nephropathy (IgAN), were included in the study. Enrolling patients began in 1994 with the intent to recruit both incident cases and cases that were already being followed up. Only Caucasian patients of Italian origin were selected. The only selection criteria were willingness of the patient to participate and a follow-up longer or equal to 4 years. Clinical and anthropometric parameters, blood pressure values, and laboratory data at the time of renal biopsy were collected. After renal biopsy, all patients were followed up regularly with laboratory analyses and clinical evaluations (at least once per year) at their respective centers. Urinary protein excretion varies considerably from day to day, but average values remain fairly constant in IgAN, at least within the first 3 years after diagnosis [23]; the average of the urinary protein excretion over the first 2 years after biopsy was therefore used for analysis. Glomerular filtration rate (GFR) was computed with the Cockcroft-Gault formula [24]. The individual rate of renal function decline was computed separately for each patient with the least squares method and expressed the loss of GFR per year (ml min-1 year-1). Twenty-eight subjects were excluded because their data set was incomplete or their DNA failed to amplify and 17 because they showed a biphasic course of their GFR over time. Their renal function remained almost normal (serum creatinine less than 1.5 mg/dl) and stable for a variable number of years, before dropping abruptly with fast progression to end stage renal disease. We and others [25] considered these cases as atypical.
###end p 27
###begin p 28
###xml 262 264 260 262 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 87 94 <span type="species:ncbi:9606">patient</span>
###xml 203 210 <span type="species:ncbi:9606">patient</span>
###xml 320 327 <span type="species:ncbi:9606">patient</span>
The minimum number of GFR determinations used to compute progression rate was four per patient, while the average number of GFR values analyzed was 9.28 +/- 0.28 (8.74-9.83, 95% confidence interval) per patient. Severity of renal damage according to Lee et al. [26] was scored by two experienced pathologists, blind for patient's clinical features, outcome, and adducin genotype, with an interrater reproducibility higher than 90%. The grading system of Lee et al. consists of a single score (grades I to V) and summarizes glomerular and, to a lesser degree, interstitial lesions. Higher grades include crescent formation and interstitial fibrosis.
###end p 28
###begin title 29
Genotyping for alpha- and beta-adducin
###end title 29
###begin p 30
###xml 127 129 127 129 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
Genotyping was carried out on an ABI PRISM 7700 Sequence Detection System using the 5' nuclease detection assay, as described [27].
###end p 30
###begin title 31
Statistical analysis
###end title 31
###begin p 32
###xml 186 187 186 187 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 295 296 295 296 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 432 434 432 434 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 439 441 439 441 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 354 359 <span type="species:ncbi:9606">human</span>
Statistical analysis was performed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA) and STATA 8 (Stata Corporation, College Station, TX, USA). Quantitative data were analyzed with Student's t test, one-way analysis of variance (ANOVA), or by simple or multiple linear regression when appropriate. A p value <0.05 (two-tailed) was considered significant. For human studies, progression rate was defined as the GFR decay each year (ml min-1 year-1) in each individual subject. First simple linear regression models were tested with renal function loss as the dependent variable and, separately one for each model, urinary protein excretion, serum creatinine, serum IgA, body mass index (BMI), and hypertension at diagnosis, gender, age of onset, and severity grading of Lee et al. as independent variables. Then, the same variables were all entered in a multiple regression model in a stepwise procedure.
###end p 32
###begin p 33
###xml 160 162 160 162 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 283 284 283 284 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 341 342 341 342 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
Test of genetic effects and interaction was performed with two-locus model fitting, and hypothesis testing was conducted via least squares regression analysis [28]. The fit of the different genetic models (additive versus dominant) was compared and evaluated based on the respective F values of each model, and the one yielding the greatest F test was assumed to be the most appropriate. The effects of the various nongenetic factors considered above (urinary protein excretion, serum creatinine, serum IgA, BMI, hypertension at diagnosis, gender, age of onset, severity grading of Lee et al.) were tested using multivariate analysis, by including them as main effects as well as interaction with genotypes. The nonsignificant effects (all of the above, except urinary protein excretion) were discarded from the model in a stepwise procedure.
###end p 33
###begin p 34
###xml 380 381 380 381 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 402 403 402 403 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
As most of the patients were recruited before generalized use of angiotensin-converting enzyme (ACE) inhibition, only about 47% of the subjects received an antihypertensive therapy, either ACE inhibitors (ACEI; 37%) or other drugs. This may affect the level of proteinuria. For this reason and for the fact that ACE inhibitor treatment was evenly distributed according to ADD1 (; p = 0.46) and ADD2 (; p = 0.37) genotype, ACE inhibition was not accounted for in the multivariate analysis but analyzed separately.
###end p 34
###begin p 35
The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
Localization of alpha- and beta-adducin in the kidney
###end title 37
###begin p 38
###xml 166 167 159 160 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 288 289 281 282 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">1</xref>
###xml 676 682 655 661 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 959 965 924 930 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">figure</italic>
###xml 682 1047 661 1012 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Immunofluorescence analysis for &#945;- and &#946;-adducin localization in renal tissues. Immunostaining was performed on mouse, rat, and human renal sections by using specific anti-adducin antibodies and indicated the presence of &#945;- and &#946;-adducin in glomerular cells. The <italic>figure</italic> shows a typical indirect immunofluorescence (&#215;400 magnification) of rat glomeruli</p>
###xml 682 1047 661 1012 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Immunofluorescence analysis for &#945;- and &#946;-adducin localization in renal tissues. Immunostaining was performed on mouse, rat, and human renal sections by using specific anti-adducin antibodies and indicated the presence of &#945;- and &#946;-adducin in glomerular cells. The <italic>figure</italic> shows a typical indirect immunofluorescence (&#215;400 magnification) of rat glomeruli</p></caption>
###xml 1047 1047 1012 1012 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig1_HTML" id="MO1"/>
###xml 676 1047 655 1012 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="39">Immunofluorescence analysis for &#945;- and &#946;-adducin localization in renal tissues. Immunostaining was performed on mouse, rat, and human renal sections by using specific anti-adducin antibodies and indicated the presence of &#945;- and &#946;-adducin in glomerular cells. The <italic>figure</italic> shows a typical indirect immunofluorescence (&#215;400 magnification) of rat glomeruli</p></caption><graphic xlink:href="109_2009_549_Fig1_HTML" id="MO1"/></fig>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 73 77 <span type="species:ncbi:10116">rats</span>
###xml 83 89 <span type="species:ncbi:9606">humans</span>
###xml 215 218 <span type="species:ncbi:10116">rat</span>
###xml 294 297 <span type="species:ncbi:10116">rat</span>
###xml 551 556 <span type="species:ncbi:10090">mouse</span>
###xml 558 561 <span type="species:ncbi:10116">rat</span>
###xml 567 572 <span type="species:ncbi:9606">human</span>
###xml 801 806 <span type="species:ncbi:10090">mouse</span>
###xml 808 811 <span type="species:ncbi:10116">rat</span>
###xml 817 822 <span type="species:ncbi:9606">human</span>
###xml 1034 1037 <span type="species:ncbi:10116">rat</span>
Immunostainings performed with specific anti-adducin antibodies in mice, rats, and humans revealed the presence of alpha- and beta-adducin in renal glomeruli. Figure 1 shows a typical immunofluorescence analysis of rat glomeruli. Immunogold electron microscopy (supplementary data, Fig. S1) in rat kidneys indicated that both proteins were ubiquitously present in glomerular cells. In particular, alpha- and beta-adducins were present in podocytes. Reverse transcriptase polymerase chain reaction, immunogold, and Western blot analysis carried out in mouse, rat, and human podocytes confirmed the presence of mRNA and protein for alpha- and beta-adducin isoforms (not shown). Fig. 1Immunofluorescence analysis for alpha- and beta-adducin localization in renal tissues. Immunostaining was performed on mouse, rat, and human renal sections by using specific anti-adducin antibodies and indicated the presence of alpha- and beta-adducin in glomerular cells. The figure shows a typical indirect immunofluorescence (x400 magnification) of rat glomeruli
###end p 38
###begin p 39
###xml 277 283 263 269 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">figure</italic>
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
###xml 126 129 <span type="species:ncbi:10116">rat</span>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 352 355 <span type="species:ncbi:10116">rat</span>
Immunofluorescence analysis for alpha- and beta-adducin localization in renal tissues. Immunostaining was performed on mouse, rat, and human renal sections by using specific anti-adducin antibodies and indicated the presence of alpha- and beta-adducin in glomerular cells. The figure shows a typical indirect immunofluorescence (x400 magnification) of rat glomeruli
###end p 39
###begin title 40
###xml 18 22 <span type="species:ncbi:10090">mice</span>
beta-Adducin null mice
###end title 40
###begin p 41
###xml 0 23 0 23 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Systolic blood pressure</bold>
###xml 168 169 165 166 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 202 208 199 205 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 343 348 337 342 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">upper</italic>
###xml 415 420 409 414 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">lower</italic>
###xml 466 468 460 462 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 484 486 478 480 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KO</italic>
###xml 576 582 570 576 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">figure</italic>
###xml 673 677 665 669 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">bars</italic>
###xml 681 682 673 674 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 208 699 205 691 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Effect of &#946;-adducin knockout on systolic blood pressure and proteinuria/creatinine ratio in mice. Indirect systolic blood pressure (<italic>upper</italic>) and urinary protein excretion normalized for urinary creatinine (<italic>lower</italic>) were measured in male and female wild-type (<italic>WT</italic>) and knockout (<italic>KO</italic>) mice at 8 and 11&#160;months of age. Similar results have been obtained at the two ages. The <italic>figure</italic> shows the results at 11&#160;months. Data are mean &#177; SEM. Mouse numbers are indicated in the <italic>bars</italic>. **<italic>p</italic>&#8201;&lt;&#8201;0.01 KO vs. WT</p>
###xml 208 699 205 691 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Effect of &#946;-adducin knockout on systolic blood pressure and proteinuria/creatinine ratio in mice. Indirect systolic blood pressure (<italic>upper</italic>) and urinary protein excretion normalized for urinary creatinine (<italic>lower</italic>) were measured in male and female wild-type (<italic>WT</italic>) and knockout (<italic>KO</italic>) mice at 8 and 11&#160;months of age. Similar results have been obtained at the two ages. The <italic>figure</italic> shows the results at 11&#160;months. Data are mean &#177; SEM. Mouse numbers are indicated in the <italic>bars</italic>. **<italic>p</italic>&#8201;&lt;&#8201;0.01 KO vs. WT</p></caption>
###xml 699 699 691 691 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig2_HTML" id="MO2"/>
###xml 202 699 199 691 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="42">Effect of &#946;-adducin knockout on systolic blood pressure and proteinuria/creatinine ratio in mice. Indirect systolic blood pressure (<italic>upper</italic>) and urinary protein excretion normalized for urinary creatinine (<italic>lower</italic>) were measured in male and female wild-type (<italic>WT</italic>) and knockout (<italic>KO</italic>) mice at 8 and 11&#160;months of age. Similar results have been obtained at the two ages. The <italic>figure</italic> shows the results at 11&#160;months. Data are mean &#177; SEM. Mouse numbers are indicated in the <italic>bars</italic>. **<italic>p</italic>&#8201;&lt;&#8201;0.01 KO vs. WT</p></caption><graphic xlink:href="109_2009_549_Fig2_HTML" id="MO2"/></fig>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 638 643 <span type="species:ncbi:10090">Mouse</span>
Systolic blood pressure SBP did not differ between male and female beta-adducin knockout mice and age- and sex-matched wild-type mice at 8 and 11 months of age. Figure 2 shows SBP in 11-month-old mice. Fig. 2Effect of beta-adducin knockout on systolic blood pressure and proteinuria/creatinine ratio in mice. Indirect systolic blood pressure (upper) and urinary protein excretion normalized for urinary creatinine (lower) were measured in male and female wild-type (WT) and knockout (KO) mice at 8 and 11 months of age. Similar results have been obtained at the two ages. The figure shows the results at 11 months. Data are mean +/- SEM. Mouse numbers are indicated in the bars. **p < 0.01 KO vs. WT
###end p 41
###begin p 42
###xml 135 140 132 137 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">upper</italic>
###xml 207 212 204 209 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">lower</italic>
###xml 258 260 255 257 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 276 278 273 275 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">KO</italic>
###xml 368 374 365 371 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">figure</italic>
###xml 465 469 460 464 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">bars</italic>
###xml 473 474 468 469 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 430 435 <span type="species:ncbi:10090">Mouse</span>
Effect of beta-adducin knockout on systolic blood pressure and proteinuria/creatinine ratio in mice. Indirect systolic blood pressure (upper) and urinary protein excretion normalized for urinary creatinine (lower) were measured in male and female wild-type (WT) and knockout (KO) mice at 8 and 11 months of age. Similar results have been obtained at the two ages. The figure shows the results at 11 months. Data are mean +/- SEM. Mouse numbers are indicated in the bars. **p < 0.01 KO vs. WT
###end p 42
###begin p 43
###xml 0 13 0 13 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Renal studies</bold>
###xml 51 52 51 52 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 55 56 55 56 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 382 383 382 383 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 878 879 863 864 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 901 902 886 887 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">2</xref>
###xml 905 911 890 896 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 1499 1500 1448 1449 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">2</xref>
###xml 911 1573 896 1522 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Immunofluorescence analysis of podocyte proteins and &#945;- and &#946;-adducin in mouse kidney sections. Immunohistochemical expression of podocyte proteins from slit diaphragm (nephrin, Fyn) and foot process cytoskeleton (synaptopodin, &#945;-actinin, ZO-1) and &#945;- and &#946;-adducin was evaluated in kidney preparations from 1.5-month-old male wild-type and &#946;-adducin knockout mice. Five mice for each group were investigated. Magnification: nephrin &#215;1,000; synaptopodin &#215;630; &#945;-actinin WT &#215;630; &#945;-actinin KO &#215;400; ZO-1 &#215;400; Fyn &#215;1,000; &#945;- and &#946;-adducin &#215;400. Figure S<xref rid="MOESM1" ref-type="">2</xref> in supplementary data shows the quantitative immunofluorescence analysis</p>
###xml 911 1573 896 1522 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Immunofluorescence analysis of podocyte proteins and &#945;- and &#946;-adducin in mouse kidney sections. Immunohistochemical expression of podocyte proteins from slit diaphragm (nephrin, Fyn) and foot process cytoskeleton (synaptopodin, &#945;-actinin, ZO-1) and &#945;- and &#946;-adducin was evaluated in kidney preparations from 1.5-month-old male wild-type and &#946;-adducin knockout mice. Five mice for each group were investigated. Magnification: nephrin &#215;1,000; synaptopodin &#215;630; &#945;-actinin WT &#215;630; &#945;-actinin KO &#215;400; ZO-1 &#215;400; Fyn &#215;1,000; &#945;- and &#946;-adducin &#215;400. Figure S<xref rid="MOESM1" ref-type="">2</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption>
###xml 1573 1573 1522 1522 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig3_HTML" id="MO3"/>
###xml 905 1573 890 1522 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="44">Immunofluorescence analysis of podocyte proteins and &#945;- and &#946;-adducin in mouse kidney sections. Immunohistochemical expression of podocyte proteins from slit diaphragm (nephrin, Fyn) and foot process cytoskeleton (synaptopodin, &#945;-actinin, ZO-1) and &#945;- and &#946;-adducin was evaluated in kidney preparations from 1.5-month-old male wild-type and &#946;-adducin knockout mice. Five mice for each group were investigated. Magnification: nephrin &#215;1,000; synaptopodin &#215;630; &#945;-actinin WT &#215;630; &#945;-actinin KO &#215;400; ZO-1 &#215;400; Fyn &#215;1,000; &#945;- and &#946;-adducin &#215;400. Figure S<xref rid="MOESM1" ref-type="">2</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption><graphic xlink:href="109_2009_549_Fig3_HTML" id="MO3"/></fig>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
###xml 727 731 <span type="species:ncbi:10090">mice</span>
###xml 867 871 <span type="species:ncbi:10090">mice</span>
###xml 991 996 <span type="species:ncbi:10090">mouse</span>
###xml 1292 1296 <span type="species:ncbi:10090">mice</span>
###xml 1303 1307 <span type="species:ncbi:10090">mice</span>
Renal studies No difference in urinary volume or Na+, K+, and creatinine excretion was detected between male and female knockout mice and wild-type controls at 8 and 11 months of age (not shown). However, compared to controls, male and female knockout mice showed a significant reduction of urinary protein excretion normalized for urinary creatinine excretion at both ages. Figure 2 shows proteinuria/creatinine ratio in 11-month-old mice. Immunostaining of proteins belonging to podocyte slit diaphragm (such as nephrin and Fyn) and foot process cytoskeleton (such as synaptopodin, alpha-actinin, and ZO-1), performed in kidney sections from male 1.5-month-old wild-type and knockout mice, showed no beta-adducin in knockout mice, a similar staining for alpha-adducin and nephrin but an increased staining for synaptopodin, alpha-actinin, ZO-1, and Fyn in knockout mice (Fig. 3; supplementary Fig. S2). Fig. 3Immunofluorescence analysis of podocyte proteins and alpha- and beta-adducin in mouse kidney sections. Immunohistochemical expression of podocyte proteins from slit diaphragm (nephrin, Fyn) and foot process cytoskeleton (synaptopodin, alpha-actinin, ZO-1) and alpha- and beta-adducin was evaluated in kidney preparations from 1.5-month-old male wild-type and beta-adducin knockout mice. Five mice for each group were investigated. Magnification: nephrin x1,000; synaptopodin x630; alpha-actinin WT x630; alpha-actinin KO x400; ZO-1 x400; Fyn x1,000; alpha- and beta-adducin x400. Figure S2 in supplementary data shows the quantitative immunofluorescence analysis
###end p 43
###begin p 44
###xml 588 589 552 553 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">2</xref>
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
###xml 381 385 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
Immunofluorescence analysis of podocyte proteins and alpha- and beta-adducin in mouse kidney sections. Immunohistochemical expression of podocyte proteins from slit diaphragm (nephrin, Fyn) and foot process cytoskeleton (synaptopodin, alpha-actinin, ZO-1) and alpha- and beta-adducin was evaluated in kidney preparations from 1.5-month-old male wild-type and beta-adducin knockout mice. Five mice for each group were investigated. Magnification: nephrin x1,000; synaptopodin x630; alpha-actinin WT x630; alpha-actinin KO x400; ZO-1 x400; Fyn x1,000; alpha- and beta-adducin x400. Figure S2 in supplementary data shows the quantitative immunofluorescence analysis
###end p 44
###begin p 45
###xml 188 189 181 182 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 417 418 406 407 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 571 572 560 561 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">3</xref>
###xml 660 661 649 650 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 699 700 685 686 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 944 950 927 933 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1388 1389 1359 1360 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1416 1417 1387 1388 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">3</xref>
###xml 950 1557 933 1525 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Western blot analysis of podocyte proteins in isolated glomeruli from &#946;-adducin knockout mice. Renal glomeruli were isolated from 1.5-month-old male wild-type and &#946;-adducin knockout mice. Five mice for each group were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies as indicated. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05 KO vs. WT. Figure S<xref rid="MOESM1" ref-type="">3</xref> in supplementary data shows the Western blots of the individual renal glomerular preparations from wild-type and &#946;-adducin knockout mice</p>
###xml 950 1557 933 1525 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Western blot analysis of podocyte proteins in isolated glomeruli from &#946;-adducin knockout mice. Renal glomeruli were isolated from 1.5-month-old male wild-type and &#946;-adducin knockout mice. Five mice for each group were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies as indicated. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05 KO vs. WT. Figure S<xref rid="MOESM1" ref-type="">3</xref> in supplementary data shows the Western blots of the individual renal glomerular preparations from wild-type and &#946;-adducin knockout mice</p></caption>
###xml 1557 1557 1525 1525 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig4_HTML" id="MO4"/>
###xml 944 1557 927 1525 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="46">Western blot analysis of podocyte proteins in isolated glomeruli from &#946;-adducin knockout mice. Renal glomeruli were isolated from 1.5-month-old male wild-type and &#946;-adducin knockout mice. Five mice for each group were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies as indicated. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05 KO vs. WT. Figure S<xref rid="MOESM1" ref-type="">3</xref> in supplementary data shows the Western blots of the individual renal glomerular preparations from wild-type and &#946;-adducin knockout mice</p></caption><graphic xlink:href="109_2009_549_Fig4_HTML" id="MO4"/></fig>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
###xml 826 830 <span type="species:ncbi:10090">mice</span>
###xml 1042 1046 <span type="species:ncbi:10090">mice</span>
###xml 1138 1142 <span type="species:ncbi:10090">mice</span>
###xml 1149 1153 <span type="species:ncbi:10090">mice</span>
###xml 1553 1557 <span type="species:ncbi:10090">mice</span>
A Western blot analysis, performed on isolated glomeruli of 1.5-month-old mice, showed no beta-adducin in knockout mice and a similar content of alpha-adducin between the two groups (Fig. 4). Total nephrin was not different while phosphorylated nephrin was significantly increased in knockout mice, together with synaptopodin, alpha-actinin, ZO-1, and Fyn. Podocin and actin were similar between the two groups (Fig. 4). The normalization of protein contents against actin did not change the pattern of differences between the two groups of mice. The supplementary Fig. S3 shows the Western blots of the individual renal glomerular preparation from wild-type (n = 5) and beta-adducin knockout mice (n = 5), probed with the specific antibodies. These data suggest that the reduced proteinuria observed in beta-adducin knockout mice, as compared to wild-type controls, is preceded by an increased expression of specific podocyte marker proteins. Fig. 4Western blot analysis of podocyte proteins in isolated glomeruli from beta-adducin knockout mice. Renal glomeruli were isolated from 1.5-month-old male wild-type and beta-adducin knockout mice. Five mice for each group were analyzed by Western blotting (10 microg protein/lane) using specific antibodies as indicated. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean +/- SEM. *p < 0.05 KO vs. WT. Figure S3 in supplementary data shows the Western blots of the individual renal glomerular preparations from wild-type and beta-adducin knockout mice
###end p 45
###begin p 46
###xml 438 439 426 427 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 466 467 454 455 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">3</xref>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
Western blot analysis of podocyte proteins in isolated glomeruli from beta-adducin knockout mice. Renal glomeruli were isolated from 1.5-month-old male wild-type and beta-adducin knockout mice. Five mice for each group were analyzed by Western blotting (10 microg protein/lane) using specific antibodies as indicated. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean +/- SEM. *p < 0.05 KO vs. WT. Figure S3 in supplementary data shows the Western blots of the individual renal glomerular preparations from wild-type and beta-adducin knockout mice
###end p 46
###begin title 47
###xml 9 12 <span type="species:ncbi:10116">rat</span>
Congenic rat substrains for alpha- and beta-adducin
###end title 47
###begin p 48
###xml 0 23 0 23 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Systolic blood pressure</bold>
###xml 38 40 38 40 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 457 458 443 444 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 615 621 594 600 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 768 772 740 744 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 841 846 813 818 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 990 992 958 960 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 1009 1011 974 976 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 1037 1040 995 998 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 1130 1134 1088 1092 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 1143 1148 1101 1106 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1221 1225 1177 1181 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">bars</italic>
###xml 1326 1327 1282 1283 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1338 1339 1294 1295 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1351 1352 1307 1308 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1372 1373 1328 1329 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 621 1387 600 1343 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="49">Systolic blood pressure and proteinuria/creatinine ratio in congenic rat substrains for &#945;- and &#946;-adducin. Indirect systolic blood pressure (<italic>left</italic>) and urinary protein excretion normalized for creatinine excretion (<italic>right</italic>) were measured in male parental hypertensive MHS and normotensive MNS rats and in congenic substrains obtained by introgressing &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>) from MHS into the MNS genetic background. The measurements have been done in rats at 3 (<italic>left</italic>) and 6 (<italic>right</italic>) months of age. Data are mean &#177; SEM. Rat numbers are indicated in the <italic>bars</italic>. No variation of heart rate was observed in any congenic substrain as compared to MNS (not shown). *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, ***<italic>p</italic>&#8201;&lt;&#8201;0.001 vs. MNS; $$<italic>p</italic>&#8201;&lt;&#8201;0.01 vs. NB</p>
###xml 621 1387 600 1343 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49">Systolic blood pressure and proteinuria/creatinine ratio in congenic rat substrains for &#945;- and &#946;-adducin. Indirect systolic blood pressure (<italic>left</italic>) and urinary protein excretion normalized for creatinine excretion (<italic>right</italic>) were measured in male parental hypertensive MHS and normotensive MNS rats and in congenic substrains obtained by introgressing &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>) from MHS into the MNS genetic background. The measurements have been done in rats at 3 (<italic>left</italic>) and 6 (<italic>right</italic>) months of age. Data are mean &#177; SEM. Rat numbers are indicated in the <italic>bars</italic>. No variation of heart rate was observed in any congenic substrain as compared to MNS (not shown). *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, ***<italic>p</italic>&#8201;&lt;&#8201;0.001 vs. MNS; $$<italic>p</italic>&#8201;&lt;&#8201;0.01 vs. NB</p></caption>
###xml 1387 1387 1343 1343 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig5_HTML" id="MO5"/>
###xml 615 1387 594 1343 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="49">Systolic blood pressure and proteinuria/creatinine ratio in congenic rat substrains for &#945;- and &#946;-adducin. Indirect systolic blood pressure (<italic>left</italic>) and urinary protein excretion normalized for creatinine excretion (<italic>right</italic>) were measured in male parental hypertensive MHS and normotensive MNS rats and in congenic substrains obtained by introgressing &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>) from MHS into the MNS genetic background. The measurements have been done in rats at 3 (<italic>left</italic>) and 6 (<italic>right</italic>) months of age. Data are mean &#177; SEM. Rat numbers are indicated in the <italic>bars</italic>. No variation of heart rate was observed in any congenic substrain as compared to MNS (not shown). *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, ***<italic>p</italic>&#8201;&lt;&#8201;0.001 vs. MNS; $$<italic>p</italic>&#8201;&lt;&#8201;0.01 vs. NB</p></caption><graphic xlink:href="109_2009_549_Fig5_HTML" id="MO5"/></fig>
###xml 396 400 <span type="species:ncbi:10116">rats</span>
###xml 690 693 <span type="species:ncbi:10116">rat</span>
###xml 917 921 <span type="species:ncbi:10116">rats</span>
###xml 1119 1123 <span type="species:ncbi:10116">rats</span>
###xml 1188 1191 <span type="species:ncbi:10116">Rat</span>
Systolic blood pressure As published [21], the introgression of alpha-adducin from MHS into the MNS genetic background (NA congenic), but not that of beta-adducin (NB congenic), significantly raises SBP in NA over MNS. Here, we have additionally demonstrated that in double-congenic strains (NAB), where polymorphic alpha- and beta-adducin genes were simultaneously transferred from MHS into MNS rats, SBP did not differ from that of MNS at any age. Figure 5 shows SBP at 3 months. These data suggest that, although beta-adducin, per se, seems not to affect SBP, it blunts the hypertensive effect of alpha-adducin. Fig. 5Systolic blood pressure and proteinuria/creatinine ratio in congenic rat substrains for alpha- and beta-adducin. Indirect systolic blood pressure (left) and urinary protein excretion normalized for creatinine excretion (right) were measured in male parental hypertensive MHS and normotensive MNS rats and in congenic substrains obtained by introgressing alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB) from MHS into the MNS genetic background. The measurements have been done in rats at 3 (left) and 6 (right) months of age. Data are mean +/- SEM. Rat numbers are indicated in the bars. No variation of heart rate was observed in any congenic substrain as compared to MNS (not shown). *p < 0.05, **p < 0.01, ***p < 0.001 vs. MNS; $$p < 0.01 vs. NB
###end p 48
###begin p 49
###xml 147 151 140 144 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 220 225 213 218 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 369 371 358 360 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 388 390 374 376 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 416 419 395 398 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 509 513 488 492 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 522 527 501 506 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 600 604 577 581 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">bars</italic>
###xml 705 706 682 683 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 717 718 694 695 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 730 731 707 708 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 751 752 728 729 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 69 72 <span type="species:ncbi:10116">rat</span>
###xml 296 300 <span type="species:ncbi:10116">rats</span>
###xml 498 502 <span type="species:ncbi:10116">rats</span>
###xml 567 570 <span type="species:ncbi:10116">Rat</span>
Systolic blood pressure and proteinuria/creatinine ratio in congenic rat substrains for alpha- and beta-adducin. Indirect systolic blood pressure (left) and urinary protein excretion normalized for creatinine excretion (right) were measured in male parental hypertensive MHS and normotensive MNS rats and in congenic substrains obtained by introgressing alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB) from MHS into the MNS genetic background. The measurements have been done in rats at 3 (left) and 6 (right) months of age. Data are mean +/- SEM. Rat numbers are indicated in the bars. No variation of heart rate was observed in any congenic substrain as compared to MNS (not shown). *p < 0.05, **p < 0.01, ***p < 0.001 vs. MNS; $$p < 0.01 vs. NB
###end p 49
###begin p 50
###xml 0 13 0 13 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Renal studies</bold>
###xml 84 86 84 86 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 87 89 87 89 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 155 157 155 157 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 463 464 456 457 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 467 468 460 461 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 716 717 709 710 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 917 919 910 912 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 920 922 913 915 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 18 22 <span type="species:ncbi:10116">rats</span>
###xml 359 362 <span type="species:ncbi:10116">rat</span>
###xml 829 833 <span type="species:ncbi:10116">rats</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
###xml 911 915 <span type="species:ncbi:10116">rats</span>
Renal studies MNS rats develop an age-dependent glomerulosclerosis and proteinuria [29-31] sustained by an increased glomerular production of thromboxane [31], while MHS are protected from a glomerular damage. To assess the involvement of alpha- and beta-adducin gene polymorphisms on the progression of renal alterations, urinary parameters were measured in rat strains at different ages (1.5, 3, 6, 8, 11 months). No urinary parameter (including 24 h urinary Na+, K+, creatinine, and proteinuria) differed among the various strains at 1.5 and 3 months of age (not shown). Protein excretion greatly increased with age in MNS and even more severely in NB, while it remained low over time in MHS, NA, and NAB. Figure 5 shows proteinuria normalized for urinary creatinine excretion at 6 months of age. The values of proteinuria in rats are higher than in mice because of the presence of glomerulosclerosis in MNS rats [29-31].
###end p 50
###begin p 51
###xml 294 295 294 295 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 352 353 352 353 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 636 637 636 637 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 763 764 759 760 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 791 792 787 788 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">4</xref>
###xml 1071 1072 1067 1068 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">5</xref>
###xml 1075 1081 1071 1077 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 1360 1362 1345 1347 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 1379 1381 1361 1363 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 1407 1410 1382 1385 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 1865 1866 1836 1837 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">4</xref>
###xml 1081 1933 1077 1904 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">Glomerular morphologic analysis in kidneys from congenic rat substrains for &#945;- and &#946;-adducin. Histomorphological studies have been conducted in kidney preparations from male parental hypertensive MHS and normotensive MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). The analysis has been performed in rats at 6&#160;months of age. The increased urinary protein excretion of MNS, which was even higher in NB, paralleled the appearance of glomerular and interstitial alterations as described in the text. The presence of MHS &#945;-adducin in MHS, NA, and NAB appeared to protect against proteinuria and glomerular damage. Five rats for each group were analyzed. Magnification: MHS and NAB &#215;400; MNS, NA, and NB &#215;250. Figure S<xref rid="MOESM1" ref-type="">4</xref> in supplementary data shows the quantitative morphometric analysis</p>
###xml 1081 1933 1077 1904 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52">Glomerular morphologic analysis in kidneys from congenic rat substrains for &#945;- and &#946;-adducin. Histomorphological studies have been conducted in kidney preparations from male parental hypertensive MHS and normotensive MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). The analysis has been performed in rats at 6&#160;months of age. The increased urinary protein excretion of MNS, which was even higher in NB, paralleled the appearance of glomerular and interstitial alterations as described in the text. The presence of MHS &#945;-adducin in MHS, NA, and NAB appeared to protect against proteinuria and glomerular damage. Five rats for each group were analyzed. Magnification: MHS and NAB &#215;400; MNS, NA, and NB &#215;250. Figure S<xref rid="MOESM1" ref-type="">4</xref> in supplementary data shows the quantitative morphometric analysis</p></caption>
###xml 1933 1933 1904 1904 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig6_HTML" id="MO6"/>
###xml 1075 1933 1071 1904 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="52">Glomerular morphologic analysis in kidneys from congenic rat substrains for &#945;- and &#946;-adducin. Histomorphological studies have been conducted in kidney preparations from male parental hypertensive MHS and normotensive MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). The analysis has been performed in rats at 6&#160;months of age. The increased urinary protein excretion of MNS, which was even higher in NB, paralleled the appearance of glomerular and interstitial alterations as described in the text. The presence of MHS &#945;-adducin in MHS, NA, and NAB appeared to protect against proteinuria and glomerular damage. Five rats for each group were analyzed. Magnification: MHS and NAB &#215;400; MNS, NA, and NB &#215;250. Figure S<xref rid="MOESM1" ref-type="">4</xref> in supplementary data shows the quantitative morphometric analysis</p></caption><graphic xlink:href="109_2009_549_Fig6_HTML" id="MO6"/></fig>
###xml 60 63 <span type="species:ncbi:10116">rat</span>
###xml 625 629 <span type="species:ncbi:10116">rats</span>
###xml 878 882 <span type="species:ncbi:10116">rats</span>
###xml 942 946 <span type="species:ncbi:10116">rats</span>
###xml 1138 1141 <span type="species:ncbi:10116">rat</span>
###xml 1309 1313 <span type="species:ncbi:10116">rats</span>
###xml 1448 1452 <span type="species:ncbi:10116">rats</span>
###xml 1767 1771 <span type="species:ncbi:10116">rats</span>
Histological studies, carried out in kidney preparations of rat strains at 3 months of age, showed normal glomeruli and normal interstitium (not shown), whereas at 6 and 11 months of age, glomerular and interstitial damage paralleled the increase of proteinuria in MNS as compared to MHS (Fig. 6). In NB, where a massive proteinuria was observed (Fig. 5), histological alterations (mesangial proliferation, mesangial matrix expansion, segmental glomerulosclerosis, interstitial leukocyte infiltration, focal areas of interstitial fibrosis, tubular dilation and giant tubular protein casts), were even more severe than in MNS rats (Fig. 6). Conversely, no histological alteration was observed in MHS, NA, and NAB strains, where MHS alpha-adducin was present (Fig. 6). The supplementary Fig. S4 shows the quantitative morphometric analysis of histological data obtained from five rats per group. Electron microscopy, carried out in 3-month-old rats, confirmed the presence of podocyte foot process effacement in MNS and NB, while NA appeared protected (supplementary Fig. S5). Fig. 6Glomerular morphologic analysis in kidneys from congenic rat substrains for alpha- and beta-adducin. Histomorphological studies have been conducted in kidney preparations from male parental hypertensive MHS and normotensive MNS rats and in congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). The analysis has been performed in rats at 6 months of age. The increased urinary protein excretion of MNS, which was even higher in NB, paralleled the appearance of glomerular and interstitial alterations as described in the text. The presence of MHS alpha-adducin in MHS, NA, and NAB appeared to protect against proteinuria and glomerular damage. Five rats for each group were analyzed. Magnification: MHS and NAB x400; MNS, NA, and NB x250. Figure S4 in supplementary data shows the quantitative morphometric analysis
###end p 51
###begin p 52
###xml 279 281 268 270 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 298 300 284 286 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 326 329 305 308 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 784 785 759 760 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">4</xref>
###xml 57 60 <span type="species:ncbi:10116">rat</span>
###xml 228 232 <span type="species:ncbi:10116">rats</span>
###xml 367 371 <span type="species:ncbi:10116">rats</span>
###xml 686 690 <span type="species:ncbi:10116">rats</span>
Glomerular morphologic analysis in kidneys from congenic rat substrains for alpha- and beta-adducin. Histomorphological studies have been conducted in kidney preparations from male parental hypertensive MHS and normotensive MNS rats and in congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). The analysis has been performed in rats at 6 months of age. The increased urinary protein excretion of MNS, which was even higher in NB, paralleled the appearance of glomerular and interstitial alterations as described in the text. The presence of MHS alpha-adducin in MHS, NA, and NAB appeared to protect against proteinuria and glomerular damage. Five rats for each group were analyzed. Magnification: MHS and NAB x400; MNS, NA, and NB x250. Figure S4 in supplementary data shows the quantitative morphometric analysis
###end p 52
###begin p 53
###xml 257 258 253 254 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 277 278 273 274 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 329 330 321 322 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig9" ref-type="fig">9</xref>
###xml 418 419 407 408 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig9" ref-type="fig">9</xref>
###xml 440 441 429 430 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 562 563 551 552 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">6</xref>
###xml 569 570 558 559 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">7</xref>
###xml 742 748 724 730 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;7</label>
###xml 1086 1088 1053 1055 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 1105 1107 1069 1071 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 1133 1136 1090 1093 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 1295 1296 1248 1249 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">6</xref>
###xml 748 1369 730 1322 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="54">Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for &#945;- and &#946;-adducin. Immunohistochemical expression of podocyte proteins (nephrin, synaptopodin, &#945;-actinin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed. Magnification: nephrin MHS and NA &#215;250; nephrin MNS, NB, and NAB &#215;400; synaptopodin and &#945;-actinin &#215;400. Figure S<xref rid="MOESM1" ref-type="">6</xref> in supplementary data shows the quantitative immunofluorescence analysis</p>
###xml 748 1369 730 1322 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="54">Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for &#945;- and &#946;-adducin. Immunohistochemical expression of podocyte proteins (nephrin, synaptopodin, &#945;-actinin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed. Magnification: nephrin MHS and NA &#215;250; nephrin MNS, NB, and NAB &#215;400; synaptopodin and &#945;-actinin &#215;400. Figure S<xref rid="MOESM1" ref-type="">6</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption>
###xml 1369 1369 1322 1322 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig7_HTML" id="MO7"/>
###xml 742 1369 724 1322 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Fig.&#160;7</label><caption><p textid="54">Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for &#945;- and &#946;-adducin. Immunohistochemical expression of podocyte proteins (nephrin, synaptopodin, &#945;-actinin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed. Magnification: nephrin MHS and NA &#215;250; nephrin MNS, NB, and NAB &#215;400; synaptopodin and &#945;-actinin &#215;400. Figure S<xref rid="MOESM1" ref-type="">6</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption><graphic xlink:href="109_2009_549_Fig7_HTML" id="MO7"/></fig>
###xml 1369 1375 1322 1328 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;8</label>
###xml 1696 1698 1638 1640 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 1715 1717 1654 1656 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 1743 1746 1675 1678 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 1838 1839 1770 1771 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">6</xref>
###xml 1375 1912 1328 1844 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="55">Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for &#945;- and &#946;-adducin. Immunohistochemical expression of podocyte proteins (ZO-1, Fyn, vimentin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed. Magnification: ZO-1, Fyn, vimentin &#215;400. Figure S<xref rid="MOESM1" ref-type="">6</xref> in supplementary data shows the quantitative immunofluorescence analysis</p>
###xml 1375 1912 1328 1844 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="55">Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for &#945;- and &#946;-adducin. Immunohistochemical expression of podocyte proteins (ZO-1, Fyn, vimentin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed. Magnification: ZO-1, Fyn, vimentin &#215;400. Figure S<xref rid="MOESM1" ref-type="">6</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption>
###xml 1912 1912 1844 1844 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig8_HTML" id="MO8"/>
###xml 1369 1912 1322 1844 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig8"><label>Fig.&#160;8</label><caption><p textid="55">Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for &#945;- and &#946;-adducin. Immunohistochemical expression of podocyte proteins (ZO-1, Fyn, vimentin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed. Magnification: ZO-1, Fyn, vimentin &#215;400. Figure S<xref rid="MOESM1" ref-type="">6</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption><graphic xlink:href="109_2009_549_Fig8_HTML" id="MO8"/></fig>
###xml 1912 1918 1844 1850 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;9</label>
###xml 2201 2203 2115 2117 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 2220 2222 2131 2133 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 2248 2251 2152 2155 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 2323 2324 2227 2228 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">7</xref>
###xml 1918 2397 1850 2301 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="56">Immunofluorescence analysis of &#945;- and &#946;-adducin in kidney sections from congenic rat substrains. Immunohistochemical expression of &#945;- and &#946;-adducin was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed (&#215;400 magnification). Figure S<xref rid="MOESM1" ref-type="">7</xref> in supplementary data shows the quantitative immunofluorescence analysis</p>
###xml 1918 2397 1850 2301 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="56">Immunofluorescence analysis of &#945;- and &#946;-adducin in kidney sections from congenic rat substrains. Immunohistochemical expression of &#945;- and &#946;-adducin was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed (&#215;400 magnification). Figure S<xref rid="MOESM1" ref-type="">7</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption>
###xml 2397 2397 2301 2301 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig9_HTML" id="MO9"/>
###xml 1912 2397 1844 2301 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig9"><label>Fig.&#160;9</label><caption><p textid="56">Immunofluorescence analysis of &#945;- and &#946;-adducin in kidney sections from congenic rat substrains. Immunohistochemical expression of &#945;- and &#946;-adducin was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed (&#215;400 magnification). Figure S<xref rid="MOESM1" ref-type="">7</xref> in supplementary data shows the quantitative immunofluorescence analysis</p></caption><graphic xlink:href="109_2009_549_Fig9_HTML" id="MO9"/></fig>
###xml 109 113 <span type="species:ncbi:10116">rats</span>
###xml 635 639 <span type="species:ncbi:10116">rats</span>
###xml 830 833 <span type="species:ncbi:10116">rat</span>
###xml 1035 1039 <span type="species:ncbi:10116">rats</span>
###xml 1144 1148 <span type="species:ncbi:10116">rats</span>
###xml 1457 1460 <span type="species:ncbi:10116">rat</span>
###xml 1645 1649 <span type="species:ncbi:10116">rats</span>
###xml 1754 1758 <span type="species:ncbi:10116">rats</span>
###xml 2006 2009 <span type="species:ncbi:10116">rat</span>
###xml 2150 2154 <span type="species:ncbi:10116">rats</span>
###xml 2259 2263 <span type="species:ncbi:10116">rats</span>
The immunohistochemical expression of podocyte proteins, evaluated in kidney preparations from 1.5-month-old rats, where no difference in proteinuria was present among all strains, showed a decreased expression of nephrin, synaptopodin, alpha-actinin (Fig. 7), ZO-1, Fyn (Fig. 8), P-cadherin (not shown), and alpha-adducin (Fig. 9) in MNS and NB strains as compared to MHS, NA, and NAB. Conversely, beta-adducin (Fig. 9) and vimentin (Fig. 8), a microfilament localized in the podocyte cell body, were normally expressed in all strains. The supplementary Figs. S6 and S7 show the quantitative analysis of these data obtained from five rats per group. Note that alpha-adducin, but not beta-adducin, was less expressed in MNS and NB (Fig. S7). Fig. 7Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for alpha- and beta-adducin. Immunohistochemical expression of podocyte proteins (nephrin, synaptopodin, alpha-actinin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). Five rats for each group were analyzed. Magnification: nephrin MHS and NA x250; nephrin MNS, NB, and NAB x400; synaptopodin and alpha-actinin x400. Figure S6 in supplementary data shows the quantitative immunofluorescence analysisFig. 8Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for alpha- and beta-adducin. Immunohistochemical expression of podocyte proteins (ZO-1, Fyn, vimentin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). Five rats for each group were analyzed. Magnification: ZO-1, Fyn, vimentin x400. Figure S6 in supplementary data shows the quantitative immunofluorescence analysisFig. 9Immunofluorescence analysis of alpha- and beta-adducin in kidney sections from congenic rat substrains. Immunohistochemical expression of alpha- and beta-adducin was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). Five rats for each group were analyzed (x400 magnification). Figure S7 in supplementary data shows the quantitative immunofluorescence analysis
###end p 53
###begin p 54
###xml 338 340 323 325 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 357 359 339 341 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 385 388 360 363 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 547 548 518 519 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">6</xref>
###xml 82 85 <span type="species:ncbi:10116">rat</span>
###xml 287 291 <span type="species:ncbi:10116">rats</span>
###xml 396 400 <span type="species:ncbi:10116">rats</span>
Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for alpha- and beta-adducin. Immunohistochemical expression of podocyte proteins (nephrin, synaptopodin, alpha-actinin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). Five rats for each group were analyzed. Magnification: nephrin MHS and NA x250; nephrin MNS, NB, and NAB x400; synaptopodin and alpha-actinin x400. Figure S6 in supplementary data shows the quantitative immunofluorescence analysis
###end p 54
###begin p 55
###xml 321 323 310 312 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 340 342 326 328 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 368 371 347 350 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 463 464 442 443 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">6</xref>
###xml 82 85 <span type="species:ncbi:10116">rat</span>
###xml 270 274 <span type="species:ncbi:10116">rats</span>
###xml 379 383 <span type="species:ncbi:10116">rats</span>
Immunofluorescence analysis of podocyte proteins in kidney sections from congenic rat substrains for alpha- and beta-adducin. Immunohistochemical expression of podocyte proteins (ZO-1, Fyn, vimentin) was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). Five rats for each group were analyzed. Magnification: ZO-1, Fyn, vimentin x400. Figure S6 in supplementary data shows the quantitative immunofluorescence analysis
###end p 55
###begin p 56
###xml 283 285 265 267 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 302 304 281 283 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 330 333 302 305 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 405 406 377 378 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">7</xref>
###xml 88 91 <span type="species:ncbi:10116">rat</span>
###xml 232 236 <span type="species:ncbi:10116">rats</span>
###xml 341 345 <span type="species:ncbi:10116">rats</span>
Immunofluorescence analysis of alpha- and beta-adducin in kidney sections from congenic rat substrains. Immunohistochemical expression of alpha- and beta-adducin was evaluated in kidney preparations from 1.5-month-old male MHS, MNS rats and in congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). Five rats for each group were analyzed (x400 magnification). Figure S7 in supplementary data shows the quantitative immunofluorescence analysis
###end p 56
###begin p 57
###xml 242 244 242 244 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig10" ref-type="fig">10</xref>
###xml 271 272 271 272 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">8</xref>
###xml 423 430 423 430 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;10</label>
###xml 664 666 653 655 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 683 685 669 671 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 711 714 690 693 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 937 938 910 911 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 949 950 922 923 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 975 976 948 949 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">8</xref>
###xml 430 1112 430 1085 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="58">Western blot analysis of nephrin and actin in isolated glomeruli from congenic rat substrains for &#945;- and &#946;-adducin. Renal glomeruli were isolated from 25&#8211;45-day-old male MHS, MNS rats and congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies against nephrin and actin. The densitometric analysis is reported as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 vs. MNS. Figure S<xref rid="MOESM1" ref-type="">8</xref> in supplementary data shows the Western blots for nephrin and actin of the individual renal glomerular preparations from rat substrains</p>
###xml 430 1112 430 1085 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="58">Western blot analysis of nephrin and actin in isolated glomeruli from congenic rat substrains for &#945;- and &#946;-adducin. Renal glomeruli were isolated from 25&#8211;45-day-old male MHS, MNS rats and congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies against nephrin and actin. The densitometric analysis is reported as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 vs. MNS. Figure S<xref rid="MOESM1" ref-type="">8</xref> in supplementary data shows the Western blots for nephrin and actin of the individual renal glomerular preparations from rat substrains</p></caption>
###xml 1112 1112 1085 1085 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig10_HTML" id="MO10"/>
###xml 423 1112 423 1085 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig10"><label>Fig.&#160;10</label><caption><p textid="58">Western blot analysis of nephrin and actin in isolated glomeruli from congenic rat substrains for &#945;- and &#946;-adducin. Renal glomeruli were isolated from 25&#8211;45-day-old male MHS, MNS rats and congenic substrains for &#945;-adducin (<italic>NA</italic>), &#946;-adducin (<italic>NB</italic>), and &#945;&#946;-adducin (<italic>NAB</italic>). Five rats for each group were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies against nephrin and actin. The densitometric analysis is reported as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 vs. MNS. Figure S<xref rid="MOESM1" ref-type="">8</xref> in supplementary data shows the Western blots for nephrin and actin of the individual renal glomerular preparations from rat substrains</p></caption><graphic xlink:href="109_2009_549_Fig10_HTML" id="MO10"/></fig>
###xml 69 73 <span type="species:ncbi:10116">rats</span>
###xml 231 235 <span type="species:ncbi:10116">rats</span>
###xml 372 375 <span type="species:ncbi:10116">rat</span>
###xml 393 397 <span type="species:ncbi:10116">rats</span>
###xml 509 512 <span type="species:ncbi:10116">rat</span>
###xml 616 620 <span type="species:ncbi:10116">rats</span>
###xml 722 726 <span type="species:ncbi:10116">rats</span>
###xml 1098 1101 <span type="species:ncbi:10116">rat</span>
A Western blot analysis of isolated glomeruli from 25- to 45-day-old rats showed a similar content of actin but a reduced expression of nephrin, either normalized or not against actin, in MNS and NB as compared to MHS, NA, and NAB rats (Fig. 10). The supplementary Fig. S8 shows the Western blots for nephrin and actin of the individual renal glomerular preparations from rat substrains. Five rats per group were analyzed. Fig. 10Western blot analysis of nephrin and actin in isolated glomeruli from congenic rat substrains for alpha- and beta-adducin. Renal glomeruli were isolated from 25-45-day-old male MHS, MNS rats and congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). Five rats for each group were analyzed by Western blotting (10 microg protein/lane) using specific antibodies against nephrin and actin. The densitometric analysis is reported as arbitrary units. Data are mean +/- SEM. *p < 0.05, **p < 0.01 vs. MNS. Figure S8 in supplementary data shows the Western blots for nephrin and actin of the individual renal glomerular preparations from rat substrains
###end p 57
###begin p 58
###xml 234 236 223 225 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 253 255 239 241 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 281 284 260 263 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NAB</italic>
###xml 507 508 480 481 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 519 520 492 493 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 545 546 518 519 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">8</xref>
###xml 79 82 <span type="species:ncbi:10116">rat</span>
###xml 186 190 <span type="species:ncbi:10116">rats</span>
###xml 292 296 <span type="species:ncbi:10116">rats</span>
###xml 668 671 <span type="species:ncbi:10116">rat</span>
Western blot analysis of nephrin and actin in isolated glomeruli from congenic rat substrains for alpha- and beta-adducin. Renal glomeruli were isolated from 25-45-day-old male MHS, MNS rats and congenic substrains for alpha-adducin (NA), beta-adducin (NB), and alphabeta-adducin (NAB). Five rats for each group were analyzed by Western blotting (10 microg protein/lane) using specific antibodies against nephrin and actin. The densitometric analysis is reported as arbitrary units. Data are mean +/- SEM. *p < 0.05, **p < 0.01 vs. MNS. Figure S8 in supplementary data shows the Western blots for nephrin and actin of the individual renal glomerular preparations from rat substrains
###end p 58
###begin p 59
###xml 277 279 269 271 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig11" ref-type="fig">11</xref>
###xml 328 329 317 318 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">9</xref>
###xml 358 360 347 349 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig11" ref-type="fig">11</xref>
###xml 548 549 537 538 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">9</xref>
###xml 645 652 634 641 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;11</label>
###xml 738 740 723 725 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 760 762 742 744 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 1134 1135 1110 1111 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1160 1161 1136 1137 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">9</xref>
###xml 652 1278 641 1254 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="60">Glomerular podocyte cultures from MNS rats and congenic substrains for &#945;-adducin (<italic>NA</italic>) and &#946;-adducin (<italic>NB</italic>). Neonatal rats (&lt;10&#160;days old) were used for podocyte culture preparations that were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies as indicated. Four preparations from MNS and NA and seven from NB rats were analyzed. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05 vs. MNS. Figure S<xref rid="MOESM1" ref-type="">9</xref> in supplementary data shows the Western blots of the individual glomerular podocyte preparations from rat substrains</p>
###xml 652 1278 641 1254 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="60">Glomerular podocyte cultures from MNS rats and congenic substrains for &#945;-adducin (<italic>NA</italic>) and &#946;-adducin (<italic>NB</italic>). Neonatal rats (&lt;10&#160;days old) were used for podocyte culture preparations that were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies as indicated. Four preparations from MNS and NA and seven from NB rats were analyzed. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05 vs. MNS. Figure S<xref rid="MOESM1" ref-type="">9</xref> in supplementary data shows the Western blots of the individual glomerular podocyte preparations from rat substrains</p></caption>
###xml 1278 1278 1254 1254 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="109_2009_549_Fig11_HTML" id="MO11"/>
###xml 645 1278 634 1254 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig11"><label>Fig.&#160;11</label><caption><p textid="60">Glomerular podocyte cultures from MNS rats and congenic substrains for &#945;-adducin (<italic>NA</italic>) and &#946;-adducin (<italic>NB</italic>). Neonatal rats (&lt;10&#160;days old) were used for podocyte culture preparations that were analyzed by Western blotting (10&#160;&#181;g protein/lane) using specific antibodies as indicated. Four preparations from MNS and NA and seven from NB rats were analyzed. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean &#177; SEM. *<italic>p</italic>&#8201;&lt;&#8201;0.05 vs. MNS. Figure S<xref rid="MOESM1" ref-type="">9</xref> in supplementary data shows the Western blots of the individual glomerular podocyte preparations from rat substrains</p></caption><graphic xlink:href="109_2009_549_Fig11_HTML" id="MO11"/></fig>
###xml 133 137 <span type="species:ncbi:10116">rats</span>
###xml 518 522 <span type="species:ncbi:10116">rats</span>
###xml 639 643 <span type="species:ncbi:10116">rats</span>
###xml 690 694 <span type="species:ncbi:10116">rats</span>
###xml 774 778 <span type="species:ncbi:10116">rats</span>
###xml 994 998 <span type="species:ncbi:10116">rats</span>
###xml 1264 1267 <span type="species:ncbi:10116">rat</span>
Furthermore, a Western blot analysis of some podocyte markers, performed on primary cultures of glomerular podocytes from 10-day-old rats, confirmed a decreased expression of nephrin, alpha-actinin, ZO-1, podocin, and alpha-adducin in MNS and NB compared to NA podocytes (Fig. 11). Conversely, beta-adducin (supplementary Fig. S9) and actin expression (Fig. 11) was similar among the three groups. The normalization of protein contents against actin did not change the pattern of differences among the three groups of rats. The supplementary Fig. S9 shows the Western blots of the individual glomerular podocyte preparations from congenic rats. Fig. 11Glomerular podocyte cultures from MNS rats and congenic substrains for alpha-adducin (NA) and beta-adducin (NB). Neonatal rats (<10 days old) were used for podocyte culture preparations that were analyzed by Western blotting (10 microg protein/lane) using specific antibodies as indicated. Four preparations from MNS and NA and seven from NB rats were analyzed. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean +/- SEM. *p < 0.05 vs. MNS. Figure S9 in supplementary data shows the Western blots of the individual glomerular podocyte preparations from rat substrains
###end p 59
###begin p 60
###xml 86 88 82 84 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 108 110 101 103 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NB</italic>
###xml 482 483 469 470 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 508 509 495 496 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">9</xref>
###xml 38 42 <span type="species:ncbi:10116">rats</span>
###xml 122 126 <span type="species:ncbi:10116">rats</span>
###xml 342 346 <span type="species:ncbi:10116">rats</span>
###xml 612 615 <span type="species:ncbi:10116">rat</span>
Glomerular podocyte cultures from MNS rats and congenic substrains for alpha-adducin (NA) and beta-adducin (NB). Neonatal rats (<10 days old) were used for podocyte culture preparations that were analyzed by Western blotting (10 microg protein/lane) using specific antibodies as indicated. Four preparations from MNS and NA and seven from NB rats were analyzed. The densitometric analysis is reported. The optical densities are expressed as arbitrary units. Data are mean +/- SEM. *p < 0.05 vs. MNS. Figure S9 in supplementary data shows the Western blots of the individual glomerular podocyte preparations from rat substrains
###end p 60
###begin p 61
###xml 389 393 <span type="species:ncbi:10116">rats</span>
The present findings suggest that the pronounced proteinuria in MNS and NB strains, carrying the beta-adducin genetic variant, is preceded by an early alteration of podocyte protein expression responsible for the changes of the glomerular filtration barrier permeability associated with protein leakage. Conversely, the MHS alpha-adducin variant seems to be protective in MHS, NA, and NAB rats.
###end p 61
###begin title 62
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Renal function loss in patients with IgA nephropathy
###end title 62
###begin p 63
###xml 56 57 56 57 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 110 111 110 111 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 111 112 111 112 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 122 123 122 123 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 148 149 148 149 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 149 150 149 150 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 160 161 160 161 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 190 191 190 191 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 191 192 191 192 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 202 203 202 203 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 251 252 251 252 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 252 253 252 253 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 263 264 263 264 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 655 656 655 656 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 656 657 656 657 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 743 744 743 744 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 744 745 744 745 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 755 756 755 756 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 767 774 767 774 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 774 833 774 833 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="64">Baseline patient demographics, clinical and laboratory data</p>
###xml 774 833 774 833 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="64">Baseline patient demographics, clinical and laboratory data</p></caption>
###xml 833 841 833 841 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Variable</th>
###xml 841 861 841 859 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Mean (range) &#177; SEM</th>
###xml 833 861 833 859 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>Variable</th><th>Mean (range) &#177; SEM</th></tr>
###xml 833 861 833 859 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Variable</th><th>Mean (range) &#177; SEM</th></tr></thead>
###xml 861 888 859 886 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Age at presentation (years)</td>
###xml 888 910 886 906 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">31.51 (16&#8211;77)&#8201;&#177;&#8201;0.77</td>
###xml 861 910 859 906 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age at presentation (years)</td><td>31.51 (16&#8211;77)&#8201;&#177;&#8201;0.77</td></tr>
###xml 910 931 906 927 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Age at biopsy (years)</td>
###xml 931 953 927 947 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">34.73 (16&#8211;77)&#8201;&#177;&#8201;0.79</td>
###xml 910 953 906 947 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age at biopsy (years)</td><td>34.73 (16&#8211;77)&#8201;&#177;&#8201;0.79</td></tr>
###xml 953 966 947 960 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Males (% men)</td>
###xml 966 977 960 971 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">247 (75.3%)</td>
###xml 953 977 947 971 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Males (% men)</td><td>247 (75.3%)</td></tr>
###xml 977 993 971 987 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Hypertensive (%)</td>
###xml 993 1004 987 998 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">158 (48.2%)</td>
###xml 977 1004 971 998 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hypertensive (%)</td><td>158 (48.2%)</td></tr>
###xml 1004 1034 998 1028 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Antihypertensive treatment (%)</td>
###xml 1034 1045 1028 1039 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">152 (46.3%)</td>
###xml 1004 1045 998 1039 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Antihypertensive treatment (%)</td><td>152 (46.3%)</td></tr>
###xml 1045 1063 1039 1057 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Macrohematuria (%)</td>
###xml 1063 1074 1057 1068 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">143 (43.6%)</td>
###xml 1045 1074 1039 1068 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Macrohematuria (%)</td><td>143 (43.6%)</td></tr>
###xml 1074 1090 1068 1084 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Body weight (kg)</td>
###xml 1090 1104 1084 1096 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">70.21&#8201;&#177;&#8201;0.84</td>
###xml 1074 1104 1068 1096 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body weight (kg)</td><td>70.21&#8201;&#177;&#8201;0.84</td></tr>
###xml 1104 1115 1096 1107 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Height (cm)</td>
###xml 1115 1130 1107 1120 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">169.25&#8201;&#177;&#8201;2.05</td>
###xml 1104 1130 1096 1120 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Height (cm)</td><td>169.25&#8201;&#177;&#8201;2.05</td></tr>
###xml 1151 1152 1141 1142 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1130 1153 1120 1143 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Body mass index (kg/m<sup>2</sup>)</td>
###xml 1153 1167 1143 1155 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">24.36&#8201;&#177;&#8201;0.22</td>
###xml 1130 1167 1120 1155 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.36&#8201;&#177;&#8201;0.22</td></tr>
###xml 1167 1191 1155 1179 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Serum creatinine (mg/dl)</td>
###xml 1191 1204 1179 1190 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.51&#8201;&#177;&#8201;0.07</td>
###xml 1167 1204 1155 1190 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Serum creatinine (mg/dl)</td><td>1.51&#8201;&#177;&#8201;0.07</td></tr>
###xml 1233 1234 1219 1220 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1204 1234 1190 1220 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Creatinine clearance (ml/min)<sup>a</sup></td>
###xml 1234 1247 1220 1231 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">80.40&#8201;&#177;&#8201;2.0</td>
###xml 1204 1247 1190 1231 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>80.40&#8201;&#177;&#8201;2.0</td></tr>
###xml 1247 1257 1231 1241 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">SBP (mmHg)</td>
###xml 1257 1272 1241 1254 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">136.39&#8201;&#177;&#8201;1.05</td>
###xml 1247 1272 1231 1254 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>SBP (mmHg)</td><td>136.39&#8201;&#177;&#8201;1.05</td></tr>
###xml 1272 1282 1254 1264 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">DBP (mmHg)</td>
###xml 1282 1296 1264 1276 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">87.55&#8201;&#177;&#8201;0.67</td>
###xml 1272 1296 1254 1276 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>DBP (mmHg)</td><td>87.55&#8201;&#177;&#8201;0.67</td></tr>
###xml 1296 1330 1276 1310 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Urinary protein excretion (g/24&#160;h)</td>
###xml 1330 1343 1310 1321 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.46&#8201;&#177;&#8201;0.07</td>
###xml 1296 1343 1276 1321 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Urinary protein excretion (g/24&#160;h)</td><td>1.46&#8201;&#177;&#8201;0.07</td></tr>
###xml 1343 1378 1321 1356 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Follow-up from presentation (years)</td>
###xml 1378 1399 1356 1375 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11.36 (4&#8211;23)&#8201;&#177;&#8201;0.38</td>
###xml 1343 1399 1321 1375 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Follow-up from presentation (years)</td><td>11.36 (4&#8211;23)&#8201;&#177;&#8201;0.38</td></tr>
###xml 1399 1428 1375 1404 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Follow-up from biopsy (years)</td>
###xml 1428 1448 1404 1422 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8.44 (4&#8211;19)&#8201;&#177;&#8201;0.37</td>
###xml 1399 1448 1375 1422 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Follow-up from biopsy (years)</td><td>8.44 (4&#8211;19)&#8201;&#177;&#8201;0.37</td></tr>
###xml 1448 1481 1422 1455 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Renal function loss (ml/min&#160;year)</td>
###xml 1481 1495 1455 1467 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5.46&#8201;&#177;&#8201;0.42</td>
###xml 1448 1495 1422 1467 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;5.46&#8201;&#177;&#8201;0.42</td></tr>
###xml 861 1495 859 1467 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age at presentation (years)</td><td>31.51 (16&#8211;77)&#8201;&#177;&#8201;0.77</td></tr><tr><td>Age at biopsy (years)</td><td>34.73 (16&#8211;77)&#8201;&#177;&#8201;0.79</td></tr><tr><td>Males (% men)</td><td>247 (75.3%)</td></tr><tr><td>Hypertensive (%)</td><td>158 (48.2%)</td></tr><tr><td>Antihypertensive treatment (%)</td><td>152 (46.3%)</td></tr><tr><td>Macrohematuria (%)</td><td>143 (43.6%)</td></tr><tr><td>Body weight (kg)</td><td>70.21&#8201;&#177;&#8201;0.84</td></tr><tr><td>Height (cm)</td><td>169.25&#8201;&#177;&#8201;2.05</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.36&#8201;&#177;&#8201;0.22</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.51&#8201;&#177;&#8201;0.07</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>80.40&#8201;&#177;&#8201;2.0</td></tr><tr><td>SBP (mmHg)</td><td>136.39&#8201;&#177;&#8201;1.05</td></tr><tr><td>DBP (mmHg)</td><td>87.55&#8201;&#177;&#8201;0.67</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.46&#8201;&#177;&#8201;0.07</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.36 (4&#8211;23)&#8201;&#177;&#8201;0.38</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.44 (4&#8211;19)&#8201;&#177;&#8201;0.37</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;5.46&#8201;&#177;&#8201;0.42</td></tr></tbody>
###xml 833 1495 833 1467 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Mean (range) &#177; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.51 (16&#8211;77)&#8201;&#177;&#8201;0.77</td></tr><tr><td>Age at biopsy (years)</td><td>34.73 (16&#8211;77)&#8201;&#177;&#8201;0.79</td></tr><tr><td>Males (% men)</td><td>247 (75.3%)</td></tr><tr><td>Hypertensive (%)</td><td>158 (48.2%)</td></tr><tr><td>Antihypertensive treatment (%)</td><td>152 (46.3%)</td></tr><tr><td>Macrohematuria (%)</td><td>143 (43.6%)</td></tr><tr><td>Body weight (kg)</td><td>70.21&#8201;&#177;&#8201;0.84</td></tr><tr><td>Height (cm)</td><td>169.25&#8201;&#177;&#8201;2.05</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.36&#8201;&#177;&#8201;0.22</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.51&#8201;&#177;&#8201;0.07</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>80.40&#8201;&#177;&#8201;2.0</td></tr><tr><td>SBP (mmHg)</td><td>136.39&#8201;&#177;&#8201;1.05</td></tr><tr><td>DBP (mmHg)</td><td>87.55&#8201;&#177;&#8201;0.67</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.46&#8201;&#177;&#8201;0.07</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.36 (4&#8211;23)&#8201;&#177;&#8201;0.38</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.44 (4&#8211;19)&#8201;&#177;&#8201;0.37</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;5.46&#8201;&#177;&#8201;0.42</td></tr></tbody></table>
###xml 1495 1705 1467 1677 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="65">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p>
###xml 1705 1706 1677 1678 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1745 1747 1717 1719 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1705 1748 1677 1720 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="66"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p>
###xml 1495 1748 1467 1720 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="65">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p textid="66"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot>
###xml 767 1748 767 1720 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="64">Baseline patient demographics, clinical and laboratory data</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Mean (range) &#177; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.51 (16&#8211;77)&#8201;&#177;&#8201;0.77</td></tr><tr><td>Age at biopsy (years)</td><td>34.73 (16&#8211;77)&#8201;&#177;&#8201;0.79</td></tr><tr><td>Males (% men)</td><td>247 (75.3%)</td></tr><tr><td>Hypertensive (%)</td><td>158 (48.2%)</td></tr><tr><td>Antihypertensive treatment (%)</td><td>152 (46.3%)</td></tr><tr><td>Macrohematuria (%)</td><td>143 (43.6%)</td></tr><tr><td>Body weight (kg)</td><td>70.21&#8201;&#177;&#8201;0.84</td></tr><tr><td>Height (cm)</td><td>169.25&#8201;&#177;&#8201;2.05</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.36&#8201;&#177;&#8201;0.22</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.51&#8201;&#177;&#8201;0.07</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>80.40&#8201;&#177;&#8201;2.0</td></tr><tr><td>SBP (mmHg)</td><td>136.39&#8201;&#177;&#8201;1.05</td></tr><tr><td>DBP (mmHg)</td><td>87.55&#8201;&#177;&#8201;0.67</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.46&#8201;&#177;&#8201;0.07</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.36 (4&#8211;23)&#8201;&#177;&#8201;0.38</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.44 (4&#8211;19)&#8201;&#177;&#8201;0.37</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;5.46&#8201;&#177;&#8201;0.42</td></tr></tbody></table><table-wrap-foot><p textid="65">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p textid="66"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot></table-wrap>
###xml 783 790 <span type="species:ncbi:9606">patient</span>
###xml 962 965 <span type="species:ncbi:9606">men</span>
Baseline data of the total sample are reported in Table 1. At univariate analysis, urinary protein excretion (R2 = 0.214, p < 0.001), hypertension (R2 = 0.103, p < 0.001), serum creatinine (R2 = 0.036, p = 0.001) at diagnosis and score of Lee et al. (R2 = 0.066, p < 0.001) correlated significantly with renal function loss, while age of onset, serum IgA concentration, gender, and BMI did not. When all were included in a multiple regression model, only urinary protein excretion and hypertension at diagnosis gave an independent significant contribution to the model. The overall variance increased very little from that explained by proteinuria alone (R2 from 0.214 to 0.237), with only minimal contribution from hypertension at diagnosis (R2 = 0.023, p = 0.002). Table 1Baseline patient demographics, clinical and laboratory dataVariableMean (range) +/- SEMAge at presentation (years)31.51 (16-77) +/- 0.77Age at biopsy (years)34.73 (16-77) +/- 0.79Males (% men)247 (75.3%)Hypertensive (%)158 (48.2%)Antihypertensive treatment (%)152 (46.3%)Macrohematuria (%)143 (43.6%)Body weight (kg)70.21 +/- 0.84Height (cm)169.25 +/- 2.05Body mass index (kg/m2)24.36 +/- 0.22Serum creatinine (mg/dl)1.51 +/- 0.07Creatinine clearance (ml/min)a80.40 +/- 2.0SBP (mmHg)136.39 +/- 1.05DBP (mmHg)87.55 +/- 0.67Urinary protein excretion (g/24 h)1.46 +/- 0.07Follow-up from presentation (years)11.36 (4-23) +/- 0.38Follow-up from biopsy (years)8.44 (4-19) +/- 0.37Renal function loss (ml/min year)-5.46 +/- 0.42If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysisaComputed with Cockcroft-Gault formula [24]
###end p 63
###begin p 64
###xml 9 16 <span type="species:ncbi:9606">patient</span>
Baseline patient demographics, clinical and laboratory data
###end p 64
###begin p 65
If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis
###end p 65
###begin p 66
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 40 42 40 42 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
aComputed with Cockcroft-Gault formula [24]
###end p 66
###begin p 67
###xml 98 99 91 92 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 185 186 178 179 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 191 192 184 185 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 349 350 342 343 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 386 387 379 380 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 390 397 383 390 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 397 467 390 453 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="68">Distribution of ADD1 (&#945;-adducin) and ADD2 (&#946;-adducin) genotypes</p>
###xml 397 467 390 453 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="68">Distribution of ADD1 (&#945;-adducin) and ADD2 (&#946;-adducin) genotypes</p></caption>
###xml 467 471 453 457 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">ADD1</th>
###xml 471 475 457 461 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">ADD2</th>
###xml 467 475 453 461 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="2">ADD1</th><th colspan="2">ADD2</th></tr>
###xml 467 475 453 461 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="2">ADD1</th><th colspan="2">ADD2</th></tr></thead>
###xml 475 484 461 470 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Gly460Gly</td>
###xml 484 495 470 481 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">231 (70.4%)</td>
###xml 495 501 481 487 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C1797C</td>
###xml 501 512 487 498 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">217 (66.2%)</td>
###xml 475 512 461 498 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Gly460Gly</td><td char="(" align="char">231 (70.4%)</td><td>C1797C</td><td char="(" align="char">217 (66.2%)</td></tr>
###xml 512 521 498 507 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Gly460Trp</td>
###xml 521 531 507 517 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">85 (25.9%)</td>
###xml 531 537 517 523 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C1797T</td>
###xml 537 547 523 533 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">95 (29.0%)</td>
###xml 512 547 498 533 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Gly460Trp</td><td char="(" align="char">85 (25.9%)</td><td>C1797T</td><td char="(" align="char">95 (29.0%)</td></tr>
###xml 547 556 533 542 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Trp460Trp</td>
###xml 556 565 542 551 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">12 (3.7%)</td>
###xml 565 571 551 557 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">T1797T</td>
###xml 571 580 557 566 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">16 (4.9%)</td>
###xml 547 580 533 566 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Trp460Trp</td><td char="(" align="char">12 (3.7%)</td><td>T1797T</td><td char="(" align="char">16 (4.9%)</td></tr>
###xml 475 580 461 566 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Gly460Gly</td><td char="(" align="char">231 (70.4%)</td><td>C1797C</td><td char="(" align="char">217 (66.2%)</td></tr><tr><td>Gly460Trp</td><td char="(" align="char">85 (25.9%)</td><td>C1797T</td><td char="(" align="char">95 (29.0%)</td></tr><tr><td>Trp460Trp</td><td char="(" align="char">12 (3.7%)</td><td>T1797T</td><td char="(" align="char">16 (4.9%)</td></tr></tbody>
###xml 467 580 453 566 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="2">ADD1</th><th colspan="2">ADD2</th></tr></thead><tbody><tr><td>Gly460Gly</td><td char="(" align="char">231 (70.4%)</td><td>C1797C</td><td char="(" align="char">217 (66.2%)</td></tr><tr><td>Gly460Trp</td><td char="(" align="char">85 (25.9%)</td><td>C1797T</td><td char="(" align="char">95 (29.0%)</td></tr><tr><td>Trp460Trp</td><td char="(" align="char">12 (3.7%)</td><td>T1797T</td><td char="(" align="char">16 (4.9%)</td></tr></tbody></table>
###xml 676 677 662 663 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 699 700 685 686 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 580 718 566 704 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="69">Genotype frequencies are in Hardy&#8211;Weinberg equilibrium (test for deviation from Hardy&#8211;Weinberg: <italic>p</italic>&#8201;=&#8201;0.826 for ADD1 and <italic>p</italic>&#8201;=&#8201;0.841 for ADD2)</p>
###xml 580 718 566 704 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="69">Genotype frequencies are in Hardy&#8211;Weinberg equilibrium (test for deviation from Hardy&#8211;Weinberg: <italic>p</italic>&#8201;=&#8201;0.826 for ADD1 and <italic>p</italic>&#8201;=&#8201;0.841 for ADD2)</p></table-wrap-foot>
###xml 390 718 383 704 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="68">Distribution of ADD1 (&#945;-adducin) and ADD2 (&#946;-adducin) genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">ADD1</th><th colspan="2">ADD2</th></tr></thead><tbody><tr><td>Gly460Gly</td><td char="(" align="char">231 (70.4%)</td><td>C1797C</td><td char="(" align="char">217 (66.2%)</td></tr><tr><td>Gly460Trp</td><td char="(" align="char">85 (25.9%)</td><td>C1797T</td><td char="(" align="char">95 (29.0%)</td></tr><tr><td>Trp460Trp</td><td char="(" align="char">12 (3.7%)</td><td>T1797T</td><td char="(" align="char">16 (4.9%)</td></tr></tbody></table><table-wrap-foot><p textid="69">Genotype frequencies are in Hardy&#8211;Weinberg equilibrium (test for deviation from Hardy&#8211;Weinberg: <italic>p</italic>&#8201;=&#8201;0.826 for ADD1 and <italic>p</italic>&#8201;=&#8201;0.841 for ADD2)</p></table-wrap-foot></table-wrap>
###xml 718 725 704 711 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 725 827 711 809 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="70">Baseline patient demographics, clinical and laboratory data according to ADD1 (&#945;-adducin) genotype</p>
###xml 725 827 711 809 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="70">Baseline patient demographics, clinical and laboratory data according to ADD1 (&#945;-adducin) genotype</p></caption>
###xml 827 835 809 817 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Variable</th>
###xml 835 850 817 832 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Gly460Gly (231)</th>
###xml 850 861 832 843 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">460Trp (97)</th>
###xml 861 862 843 844 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 861 862 843 844 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>p</italic></th>
###xml 827 862 809 844 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Variable</th><th>Gly460Gly (231)</th><th>460Trp (97)</th><th rowspan="2"><italic>p</italic></th></tr>
###xml 862 882 844 862 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Mean (range) &#177; SEM</th>
###xml 882 902 862 880 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Mean (range) &#177; SEM</th>
###xml 862 902 844 880 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>Mean (range) &#177; SEM</th><th>Mean (range) &#177; SEM</th></tr>
###xml 827 902 809 880 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Variable</th><th>Gly460Gly (231)</th><th>460Trp (97)</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>Mean (range) &#177; SEM</th><th>Mean (range) &#177; SEM</th></tr></thead>
###xml 902 929 880 907 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Age at presentation (years)</td>
###xml 929 950 907 926 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">31.5 (16&#8211;77)&#8201;&#177;&#8201;0.91</td>
###xml 950 971 926 945 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">31.6 (15&#8211;72)&#8201;&#177;&#8201;1.42</td>
###xml 971 975 945 949 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 902 975 880 949 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age at presentation (years)</td><td>31.5 (16&#8211;77)&#8201;&#177;&#8201;0.91</td><td>31.6 (15&#8211;72)&#8201;&#177;&#8201;1.42</td><td>n.s.</td></tr>
###xml 975 996 949 970 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Age at biopsy (years)</td>
###xml 996 1017 970 989 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">34.8 (16&#8211;77)&#8201;&#177;&#8201;0.95</td>
###xml 1017 1038 989 1008 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">34.6 (17&#8211;72)&#8201;&#177;&#8201;1.43</td>
###xml 1038 1042 1008 1012 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 975 1042 949 1012 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age at biopsy (years)</td><td>34.8 (16&#8211;77)&#8201;&#177;&#8201;0.95</td><td>34.6 (17&#8211;72)&#8201;&#177;&#8201;1.43</td><td>n.s.</td></tr>
###xml 1042 1055 1012 1025 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Males (% men)</td>
###xml 1055 1064 1025 1034 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">175 (76%)</td>
###xml 1064 1072 1034 1042 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">72 (74%)</td>
###xml 1072 1076 1042 1046 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1042 1076 1012 1046 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Males (% men)</td><td>175 (76%)</td><td>72 (74%)</td><td>n.s.</td></tr>
###xml 1076 1092 1046 1062 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Hypertensive (%)</td>
###xml 1092 1101 1062 1071 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">144 (62%)</td>
###xml 1101 1109 1071 1079 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">44 (45%)</td>
###xml 1109 1113 1079 1083 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1076 1113 1046 1083 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hypertensive (%)</td><td>144 (62%)</td><td>44 (45%)</td><td>n.s.</td></tr>
###xml 1113 1143 1083 1113 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Antihypertensive treatment (%)</td>
###xml 1143 1152 1113 1122 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">108 (47%)</td>
###xml 1152 1160 1122 1130 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">44 (45%)</td>
###xml 1160 1164 1130 1134 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1113 1164 1083 1134 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Antihypertensive treatment (%)</td><td>108 (47%)</td><td>44 (45%)</td><td>n.s.</td></tr>
###xml 1164 1182 1134 1152 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Macrohematuria (%)</td>
###xml 1182 1190 1152 1160 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">94 (41%)</td>
###xml 1190 1198 1160 1168 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">49 (50%)</td>
###xml 1198 1202 1168 1172 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1164 1202 1134 1172 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Macrohematuria (%)</td><td>94 (41%)</td><td>49 (50%)</td><td>n.s.</td></tr>
###xml 1202 1218 1172 1188 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Body weight (kg)</td>
###xml 1218 1231 1188 1199 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">70.3&#8201;&#177;&#8201;0.71</td>
###xml 1231 1244 1199 1210 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">70.1&#8201;&#177;&#8201;1.02</td>
###xml 1244 1248 1210 1214 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1202 1248 1172 1214 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body weight (kg)</td><td>70.3&#8201;&#177;&#8201;0.71</td><td>70.1&#8201;&#177;&#8201;1.02</td><td>n.s.</td></tr>
###xml 1248 1259 1214 1225 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Height (cm)</td>
###xml 1259 1273 1225 1237 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">169.4&#8201;&#177;&#8201;0.56</td>
###xml 1273 1287 1237 1249 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">168.8&#8201;&#177;&#8201;0.76</td>
###xml 1287 1291 1249 1253 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1248 1291 1214 1253 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Height (cm)</td><td>169.4&#8201;&#177;&#8201;0.56</td><td>168.8&#8201;&#177;&#8201;0.76</td><td>n.s.</td></tr>
###xml 1312 1313 1274 1275 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1291 1314 1253 1276 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Body mass index (kg/m<sup>2</sup>)</td>
###xml 1314 1327 1276 1287 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">24.3&#8201;&#177;&#8201;0.20</td>
###xml 1327 1340 1287 1298 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">24.5&#8201;&#177;&#8201;0.32</td>
###xml 1340 1344 1298 1302 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1291 1344 1253 1302 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.3&#8201;&#177;&#8201;0.20</td><td>24.5&#8201;&#177;&#8201;0.32</td><td>n.s.</td></tr>
###xml 1344 1368 1302 1326 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Serum creatinine (mg/dl)</td>
###xml 1368 1381 1326 1337 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.52&#8201;&#177;&#8201;0.10</td>
###xml 1381 1394 1337 1348 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.47&#8201;&#177;&#8201;0.08</td>
###xml 1394 1398 1348 1352 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1344 1398 1302 1352 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Serum creatinine (mg/dl)</td><td>1.52&#8201;&#177;&#8201;0.10</td><td>1.47&#8201;&#177;&#8201;0.08</td><td>n.s.</td></tr>
###xml 1427 1428 1381 1382 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1398 1428 1352 1382 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Creatinine clearance (ml/min)<sup>a</sup></td>
###xml 1428 1441 1382 1393 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">81.0&#8201;&#177;&#8201;2.24</td>
###xml 1441 1454 1393 1404 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">79.0&#8201;&#177;&#8201;3.90</td>
###xml 1454 1458 1404 1408 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1398 1458 1352 1408 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>81.0&#8201;&#177;&#8201;2.24</td><td>79.0&#8201;&#177;&#8201;3.90</td><td>n.s.</td></tr>
###xml 1458 1468 1408 1418 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">SBP (mmHg)</td>
###xml 1468 1482 1418 1430 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">135.8&#8201;&#177;&#8201;1.20</td>
###xml 1482 1496 1430 1442 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">137.7&#8201;&#177;&#8201;1.90</td>
###xml 1496 1500 1442 1446 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1458 1500 1408 1446 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>SBP (mmHg)</td><td>135.8&#8201;&#177;&#8201;1.20</td><td>137.7&#8201;&#177;&#8201;1.90</td><td>n.s.</td></tr>
###xml 1500 1510 1446 1456 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">DBP (mmHg)</td>
###xml 1510 1523 1456 1467 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">87.2&#8201;&#177;&#8201;0.80</td>
###xml 1523 1536 1467 1478 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">88.5&#8201;&#177;&#8201;1.22</td>
###xml 1536 1540 1478 1482 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1500 1540 1446 1482 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>DBP (mmHg)</td><td>87.2&#8201;&#177;&#8201;0.80</td><td>88.5&#8201;&#177;&#8201;1.22</td><td>n.s.</td></tr>
###xml 1540 1574 1482 1516 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Urinary protein excretion (g/24&#160;h)</td>
###xml 1574 1587 1516 1527 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.47&#8201;&#177;&#8201;0.08</td>
###xml 1587 1600 1527 1538 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.46&#8201;&#177;&#8201;0.15</td>
###xml 1600 1604 1538 1542 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1540 1604 1482 1542 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Urinary protein excretion (g/24&#160;h)</td><td>1.47&#8201;&#177;&#8201;0.08</td><td>1.46&#8201;&#177;&#8201;0.15</td><td>n.s.</td></tr>
###xml 1604 1639 1542 1577 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Follow-up from presentation (years)</td>
###xml 1639 1659 1577 1595 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11.3 (4&#8211;23)&#8201;&#177;&#8201;0.35</td>
###xml 1659 1679 1595 1613 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11.4 (4&#8211;23)&#8201;&#177;&#8201;0.55</td>
###xml 1679 1683 1613 1617 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1604 1683 1542 1617 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Follow-up from presentation (years)</td><td>11.3 (4&#8211;23)&#8201;&#177;&#8201;0.35</td><td>11.4 (4&#8211;23)&#8201;&#177;&#8201;0.55</td><td>n.s.</td></tr>
###xml 1683 1712 1617 1646 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Follow-up from biopsy (years)</td>
###xml 1712 1731 1646 1663 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8.3 (4&#8211;19)&#8201;&#177;&#8201;0.30</td>
###xml 1731 1750 1663 1680 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8.7 (4&#8211;19)&#8201;&#177;&#8201;0.49</td>
###xml 1750 1754 1680 1684 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1683 1754 1617 1684 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Follow-up from biopsy (years)</td><td>8.3 (4&#8211;19)&#8201;&#177;&#8201;0.30</td><td>8.7 (4&#8211;19)&#8201;&#177;&#8201;0.49</td><td>n.s.</td></tr>
###xml 1754 1787 1684 1717 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Renal function loss (ml/min&#160;year)</td>
###xml 1787 1801 1717 1729 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5.04&#8201;&#177;&#8201;0.42</td>
###xml 1801 1815 1729 1741 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6.46&#8201;&#177;&#8201;1.00</td>
###xml 1815 1819 1741 1745 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 1754 1819 1684 1745 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;5.04&#8201;&#177;&#8201;0.42</td><td>&#8722;6.46&#8201;&#177;&#8201;1.00</td><td>n.s.</td></tr>
###xml 902 1819 880 1745 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age at presentation (years)</td><td>31.5 (16&#8211;77)&#8201;&#177;&#8201;0.91</td><td>31.6 (15&#8211;72)&#8201;&#177;&#8201;1.42</td><td>n.s.</td></tr><tr><td>Age at biopsy (years)</td><td>34.8 (16&#8211;77)&#8201;&#177;&#8201;0.95</td><td>34.6 (17&#8211;72)&#8201;&#177;&#8201;1.43</td><td>n.s.</td></tr><tr><td>Males (% men)</td><td>175 (76%)</td><td>72 (74%)</td><td>n.s.</td></tr><tr><td>Hypertensive (%)</td><td>144 (62%)</td><td>44 (45%)</td><td>n.s.</td></tr><tr><td>Antihypertensive treatment (%)</td><td>108 (47%)</td><td>44 (45%)</td><td>n.s.</td></tr><tr><td>Macrohematuria (%)</td><td>94 (41%)</td><td>49 (50%)</td><td>n.s.</td></tr><tr><td>Body weight (kg)</td><td>70.3&#8201;&#177;&#8201;0.71</td><td>70.1&#8201;&#177;&#8201;1.02</td><td>n.s.</td></tr><tr><td>Height (cm)</td><td>169.4&#8201;&#177;&#8201;0.56</td><td>168.8&#8201;&#177;&#8201;0.76</td><td>n.s.</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.3&#8201;&#177;&#8201;0.20</td><td>24.5&#8201;&#177;&#8201;0.32</td><td>n.s.</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.52&#8201;&#177;&#8201;0.10</td><td>1.47&#8201;&#177;&#8201;0.08</td><td>n.s.</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>81.0&#8201;&#177;&#8201;2.24</td><td>79.0&#8201;&#177;&#8201;3.90</td><td>n.s.</td></tr><tr><td>SBP (mmHg)</td><td>135.8&#8201;&#177;&#8201;1.20</td><td>137.7&#8201;&#177;&#8201;1.90</td><td>n.s.</td></tr><tr><td>DBP (mmHg)</td><td>87.2&#8201;&#177;&#8201;0.80</td><td>88.5&#8201;&#177;&#8201;1.22</td><td>n.s.</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.47&#8201;&#177;&#8201;0.08</td><td>1.46&#8201;&#177;&#8201;0.15</td><td>n.s.</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.3 (4&#8211;23)&#8201;&#177;&#8201;0.35</td><td>11.4 (4&#8211;23)&#8201;&#177;&#8201;0.55</td><td>n.s.</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.3 (4&#8211;19)&#8201;&#177;&#8201;0.30</td><td>8.7 (4&#8211;19)&#8201;&#177;&#8201;0.49</td><td>n.s.</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;5.04&#8201;&#177;&#8201;0.42</td><td>&#8722;6.46&#8201;&#177;&#8201;1.00</td><td>n.s.</td></tr></tbody>
###xml 827 1819 809 1745 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th>Gly460Gly (231)</th><th>460Trp (97)</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>Mean (range) &#177; SEM</th><th>Mean (range) &#177; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.5 (16&#8211;77)&#8201;&#177;&#8201;0.91</td><td>31.6 (15&#8211;72)&#8201;&#177;&#8201;1.42</td><td>n.s.</td></tr><tr><td>Age at biopsy (years)</td><td>34.8 (16&#8211;77)&#8201;&#177;&#8201;0.95</td><td>34.6 (17&#8211;72)&#8201;&#177;&#8201;1.43</td><td>n.s.</td></tr><tr><td>Males (% men)</td><td>175 (76%)</td><td>72 (74%)</td><td>n.s.</td></tr><tr><td>Hypertensive (%)</td><td>144 (62%)</td><td>44 (45%)</td><td>n.s.</td></tr><tr><td>Antihypertensive treatment (%)</td><td>108 (47%)</td><td>44 (45%)</td><td>n.s.</td></tr><tr><td>Macrohematuria (%)</td><td>94 (41%)</td><td>49 (50%)</td><td>n.s.</td></tr><tr><td>Body weight (kg)</td><td>70.3&#8201;&#177;&#8201;0.71</td><td>70.1&#8201;&#177;&#8201;1.02</td><td>n.s.</td></tr><tr><td>Height (cm)</td><td>169.4&#8201;&#177;&#8201;0.56</td><td>168.8&#8201;&#177;&#8201;0.76</td><td>n.s.</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.3&#8201;&#177;&#8201;0.20</td><td>24.5&#8201;&#177;&#8201;0.32</td><td>n.s.</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.52&#8201;&#177;&#8201;0.10</td><td>1.47&#8201;&#177;&#8201;0.08</td><td>n.s.</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>81.0&#8201;&#177;&#8201;2.24</td><td>79.0&#8201;&#177;&#8201;3.90</td><td>n.s.</td></tr><tr><td>SBP (mmHg)</td><td>135.8&#8201;&#177;&#8201;1.20</td><td>137.7&#8201;&#177;&#8201;1.90</td><td>n.s.</td></tr><tr><td>DBP (mmHg)</td><td>87.2&#8201;&#177;&#8201;0.80</td><td>88.5&#8201;&#177;&#8201;1.22</td><td>n.s.</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.47&#8201;&#177;&#8201;0.08</td><td>1.46&#8201;&#177;&#8201;0.15</td><td>n.s.</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.3 (4&#8211;23)&#8201;&#177;&#8201;0.35</td><td>11.4 (4&#8211;23)&#8201;&#177;&#8201;0.55</td><td>n.s.</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.3 (4&#8211;19)&#8201;&#177;&#8201;0.30</td><td>8.7 (4&#8211;19)&#8201;&#177;&#8201;0.49</td><td>n.s.</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;5.04&#8201;&#177;&#8201;0.42</td><td>&#8722;6.46&#8201;&#177;&#8201;1.00</td><td>n.s.</td></tr></tbody></table>
###xml 1819 2029 1745 1955 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="71">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p>
###xml 2029 2030 1955 1956 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2069 2071 1995 1997 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 2029 2072 1955 1998 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="72"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p>
###xml 1819 2072 1745 1998 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="71">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p textid="72"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot>
###xml 718 2072 704 1998 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="70">Baseline patient demographics, clinical and laboratory data according to ADD1 (&#945;-adducin) genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th>Gly460Gly (231)</th><th>460Trp (97)</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>Mean (range) &#177; SEM</th><th>Mean (range) &#177; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.5 (16&#8211;77)&#8201;&#177;&#8201;0.91</td><td>31.6 (15&#8211;72)&#8201;&#177;&#8201;1.42</td><td>n.s.</td></tr><tr><td>Age at biopsy (years)</td><td>34.8 (16&#8211;77)&#8201;&#177;&#8201;0.95</td><td>34.6 (17&#8211;72)&#8201;&#177;&#8201;1.43</td><td>n.s.</td></tr><tr><td>Males (% men)</td><td>175 (76%)</td><td>72 (74%)</td><td>n.s.</td></tr><tr><td>Hypertensive (%)</td><td>144 (62%)</td><td>44 (45%)</td><td>n.s.</td></tr><tr><td>Antihypertensive treatment (%)</td><td>108 (47%)</td><td>44 (45%)</td><td>n.s.</td></tr><tr><td>Macrohematuria (%)</td><td>94 (41%)</td><td>49 (50%)</td><td>n.s.</td></tr><tr><td>Body weight (kg)</td><td>70.3&#8201;&#177;&#8201;0.71</td><td>70.1&#8201;&#177;&#8201;1.02</td><td>n.s.</td></tr><tr><td>Height (cm)</td><td>169.4&#8201;&#177;&#8201;0.56</td><td>168.8&#8201;&#177;&#8201;0.76</td><td>n.s.</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.3&#8201;&#177;&#8201;0.20</td><td>24.5&#8201;&#177;&#8201;0.32</td><td>n.s.</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.52&#8201;&#177;&#8201;0.10</td><td>1.47&#8201;&#177;&#8201;0.08</td><td>n.s.</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>81.0&#8201;&#177;&#8201;2.24</td><td>79.0&#8201;&#177;&#8201;3.90</td><td>n.s.</td></tr><tr><td>SBP (mmHg)</td><td>135.8&#8201;&#177;&#8201;1.20</td><td>137.7&#8201;&#177;&#8201;1.90</td><td>n.s.</td></tr><tr><td>DBP (mmHg)</td><td>87.2&#8201;&#177;&#8201;0.80</td><td>88.5&#8201;&#177;&#8201;1.22</td><td>n.s.</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.47&#8201;&#177;&#8201;0.08</td><td>1.46&#8201;&#177;&#8201;0.15</td><td>n.s.</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.3 (4&#8211;23)&#8201;&#177;&#8201;0.35</td><td>11.4 (4&#8211;23)&#8201;&#177;&#8201;0.55</td><td>n.s.</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.3 (4&#8211;19)&#8201;&#177;&#8201;0.30</td><td>8.7 (4&#8211;19)&#8201;&#177;&#8201;0.49</td><td>n.s.</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;5.04&#8201;&#177;&#8201;0.42</td><td>&#8722;6.46&#8201;&#177;&#8201;1.00</td><td>n.s.</td></tr></tbody></table><table-wrap-foot><p textid="71">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p textid="72"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot></table-wrap>
###xml 2072 2079 1998 2005 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 2079 2180 2005 2103 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="73">Baseline patient demographics, clinical and laboratory data according to ADD2 (&#946;-adducin) genotype</p>
###xml 2079 2180 2005 2103 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="73">Baseline patient demographics, clinical and laboratory data according to ADD2 (&#946;-adducin) genotype</p></caption>
###xml 2180 2188 2103 2111 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Variable</th>
###xml 2188 2200 2111 2123 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C1797C (217)</th>
###xml 2200 2211 2123 2134 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1797T (111)</th>
###xml 2211 2212 2134 2135 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2211 2212 2134 2135 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>p</italic></th>
###xml 2180 2212 2103 2135 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Variable</th><th>C1797C (217)</th><th>1797T (111)</th><th rowspan="2"><italic>p</italic></th></tr>
###xml 2212 2232 2135 2153 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Mean (range) &#177; SEM</th>
###xml 2232 2252 2153 2171 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Mean (range) &#177; SEM</th>
###xml 2212 2252 2135 2171 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>Mean (range) &#177; SEM</th><th>Mean (range) &#177; SEM</th></tr>
###xml 2180 2252 2103 2171 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Variable</th><th>C1797C (217)</th><th>1797T (111)</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>Mean (range) &#177; SEM</th><th>Mean (range) &#177; SEM</th></tr></thead>
###xml 2252 2279 2171 2198 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Age at presentation (years)</td>
###xml 2279 2300 2198 2217 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">31.5 (16&#8211;77)&#8201;&#177;&#8201;0.95</td>
###xml 2300 2321 2217 2236 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">31.6 (16&#8211;72)&#8201;&#177;&#8201;1.31</td>
###xml 2321 2325 2236 2240 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2252 2325 2171 2240 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age at presentation (years)</td><td>31.5 (16&#8211;77)&#8201;&#177;&#8201;0.95</td><td>31.6 (16&#8211;72)&#8201;&#177;&#8201;1.31</td><td>n.s.</td></tr>
###xml 2325 2346 2240 2261 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Age at biopsy (years)</td>
###xml 2346 2367 2261 2280 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">34.9 (16&#8211;77)&#8201;&#177;&#8201;0.99</td>
###xml 2367 2388 2280 2299 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">34.4 (16&#8211;72)&#8201;&#177;&#8201;1.33</td>
###xml 2388 2392 2299 2303 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2325 2392 2240 2303 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age at biopsy (years)</td><td>34.9 (16&#8211;77)&#8201;&#177;&#8201;0.99</td><td>34.4 (16&#8211;72)&#8201;&#177;&#8201;1.33</td><td>n.s.</td></tr>
###xml 2392 2405 2303 2316 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Males (% men)</td>
###xml 2405 2414 2316 2325 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">168 (77%)</td>
###xml 2414 2422 2325 2333 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">79 (71%)</td>
###xml 2422 2426 2333 2337 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2392 2426 2303 2337 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Males (% men)</td><td>168 (77%)</td><td>79 (71%)</td><td>n.s.</td></tr>
###xml 2426 2442 2337 2353 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Hypertensive (%)</td>
###xml 2442 2450 2353 2361 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">99 (46%)</td>
###xml 2450 2458 2361 2369 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">59 (53%)</td>
###xml 2458 2462 2369 2373 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2426 2462 2337 2373 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hypertensive (%)</td><td>99 (46%)</td><td>59 (53%)</td><td>n.s.</td></tr>
###xml 2462 2492 2373 2403 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Antihypertensive treatment (%)</td>
###xml 2492 2500 2403 2411 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">94 (43%)</td>
###xml 2500 2508 2411 2419 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">58 (52%)</td>
###xml 2508 2512 2419 2423 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2462 2512 2373 2423 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Antihypertensive treatment (%)</td><td>94 (43%)</td><td>58 (52%)</td><td>n.s.</td></tr>
###xml 2512 2530 2423 2441 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Macrohematuria (%)</td>
###xml 2530 2539 2441 2450 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">102 (47%)</td>
###xml 2539 2547 2450 2458 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">41 (37%)</td>
###xml 2547 2551 2458 2462 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2512 2551 2423 2462 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Macrohematuria (%)</td><td>102 (47%)</td><td>41 (37%)</td><td>n.s.</td></tr>
###xml 2551 2567 2462 2478 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Body weight (kg)</td>
###xml 2567 2580 2478 2489 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">70.9&#8201;&#177;&#8201;0.72</td>
###xml 2580 2593 2489 2500 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">68.9&#8201;&#177;&#8201;1.00</td>
###xml 2593 2597 2500 2504 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2551 2597 2462 2504 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body weight (kg)</td><td>70.9&#8201;&#177;&#8201;0.72</td><td>68.9&#8201;&#177;&#8201;1.00</td><td>n.s.</td></tr>
###xml 2597 2608 2504 2515 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Height (cm)</td>
###xml 2608 2622 2515 2527 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">169.4&#8201;&#177;&#8201;0.53</td>
###xml 2622 2636 2527 2539 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">168.8&#8201;&#177;&#8201;0.80</td>
###xml 2636 2640 2539 2543 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2597 2640 2504 2543 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Height (cm)</td><td>169.4&#8201;&#177;&#8201;0.53</td><td>168.8&#8201;&#177;&#8201;0.80</td><td>n.s.</td></tr>
###xml 2661 2662 2564 2565 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2640 2663 2543 2566 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Body mass index (kg/m<sup>2</sup>)</td>
###xml 2663 2676 2566 2577 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">24.5&#8201;&#177;&#8201;0.22</td>
###xml 2676 2689 2577 2588 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">23.9&#8201;&#177;&#8201;0.27</td>
###xml 2689 2693 2588 2592 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2640 2693 2543 2592 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.5&#8201;&#177;&#8201;0.22</td><td>23.9&#8201;&#177;&#8201;0.27</td><td>n.s.</td></tr>
###xml 2693 2717 2592 2616 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Serum creatinine (mg/dl)</td>
###xml 2717 2730 2616 2627 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.48&#8201;&#177;&#8201;0.07</td>
###xml 2730 2743 2627 2638 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.56&#8201;&#177;&#8201;0.16</td>
###xml 2743 2747 2638 2642 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2693 2747 2592 2642 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Serum creatinine (mg/dl)</td><td>1.48&#8201;&#177;&#8201;0.07</td><td>1.56&#8201;&#177;&#8201;0.16</td><td>n.s.</td></tr>
###xml 2776 2777 2671 2672 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2747 2777 2642 2672 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Creatinine clearance (ml/min)<sup>a</sup></td>
###xml 2777 2790 2672 2683 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">82.2&#8201;&#177;&#8201;2.51</td>
###xml 2790 2803 2683 2694 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">76.9&#8201;&#177;&#8201;3.02</td>
###xml 2803 2807 2694 2698 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2747 2807 2642 2698 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>82.2&#8201;&#177;&#8201;2.51</td><td>76.9&#8201;&#177;&#8201;3.02</td><td>n.s.</td></tr>
###xml 2807 2817 2698 2708 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">SBP (mmHg)</td>
###xml 2817 2831 2708 2720 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">134.8&#8201;&#177;&#8201;1.12</td>
###xml 2831 2845 2720 2732 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">139.5&#8201;&#177;&#8201;2.01</td>
###xml 2845 2850 2732 2737 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.041</td>
###xml 2807 2850 2698 2737 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>SBP (mmHg)</td><td>134.8&#8201;&#177;&#8201;1.12</td><td>139.5&#8201;&#177;&#8201;2.01</td><td>0.041</td></tr>
###xml 2850 2860 2737 2747 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">DBP (mmHg)</td>
###xml 2860 2873 2747 2758 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">86.6&#8201;&#177;&#8201;0.78</td>
###xml 2873 2886 2758 2769 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">89.3&#8201;&#177;&#8201;1.22</td>
###xml 2886 2891 2769 2774 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.054</td>
###xml 2850 2891 2737 2774 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>DBP (mmHg)</td><td>86.6&#8201;&#177;&#8201;0.78</td><td>89.3&#8201;&#177;&#8201;1.22</td><td>0.054</td></tr>
###xml 2891 2925 2774 2808 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Urinary protein excretion (g/24&#160;h)</td>
###xml 2925 2938 2808 2819 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.38&#8201;&#177;&#8201;0.09</td>
###xml 2938 2951 2819 2830 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.63&#8201;&#177;&#8201;0.13</td>
###xml 2951 2955 2830 2834 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2891 2955 2774 2834 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Urinary protein excretion (g/24&#160;h)</td><td>1.38&#8201;&#177;&#8201;0.09</td><td>1.63&#8201;&#177;&#8201;0.13</td><td>n.s.</td></tr>
###xml 2955 2990 2834 2869 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Follow-up from presentation (years)</td>
###xml 2990 3010 2869 2887 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11.4 (4&#8211;23)&#8201;&#177;&#8201;0.34</td>
###xml 3010 3030 2887 2905 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11.3 (4&#8211;21)&#8201;&#177;&#8201;0.58</td>
###xml 3030 3034 2905 2909 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 2955 3034 2834 2909 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Follow-up from presentation (years)</td><td>11.4 (4&#8211;23)&#8201;&#177;&#8201;0.34</td><td>11.3 (4&#8211;21)&#8201;&#177;&#8201;0.58</td><td>n.s.</td></tr>
###xml 3034 3063 2909 2938 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Follow-up from biopsy (years)</td>
###xml 3063 3082 2938 2955 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8.4 (4&#8211;19)&#8201;&#177;&#8201;0.24</td>
###xml 3082 3101 2955 2972 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8.6 (4&#8211;19)&#8201;&#177;&#8201;0.49</td>
###xml 3101 3105 2972 2976 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</td>
###xml 3034 3105 2909 2976 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Follow-up from biopsy (years)</td><td>8.4 (4&#8211;19)&#8201;&#177;&#8201;0.24</td><td>8.6 (4&#8211;19)&#8201;&#177;&#8201;0.49</td><td>n.s.</td></tr>
###xml 3105 3138 2976 3009 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Renal function loss (ml/min&#160;year)</td>
###xml 3138 3152 3009 3021 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4.77&#8201;&#177;&#8201;0.41</td>
###xml 3152 3166 3021 3033 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6.82&#8201;&#177;&#8201;0.92</td>
###xml 3166 3171 3033 3038 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.043</td>
###xml 3105 3171 2976 3038 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;4.77&#8201;&#177;&#8201;0.41</td><td>&#8722;6.82&#8201;&#177;&#8201;0.92</td><td>0.043</td></tr>
###xml 2252 3171 2171 3038 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age at presentation (years)</td><td>31.5 (16&#8211;77)&#8201;&#177;&#8201;0.95</td><td>31.6 (16&#8211;72)&#8201;&#177;&#8201;1.31</td><td>n.s.</td></tr><tr><td>Age at biopsy (years)</td><td>34.9 (16&#8211;77)&#8201;&#177;&#8201;0.99</td><td>34.4 (16&#8211;72)&#8201;&#177;&#8201;1.33</td><td>n.s.</td></tr><tr><td>Males (% men)</td><td>168 (77%)</td><td>79 (71%)</td><td>n.s.</td></tr><tr><td>Hypertensive (%)</td><td>99 (46%)</td><td>59 (53%)</td><td>n.s.</td></tr><tr><td>Antihypertensive treatment (%)</td><td>94 (43%)</td><td>58 (52%)</td><td>n.s.</td></tr><tr><td>Macrohematuria (%)</td><td>102 (47%)</td><td>41 (37%)</td><td>n.s.</td></tr><tr><td>Body weight (kg)</td><td>70.9&#8201;&#177;&#8201;0.72</td><td>68.9&#8201;&#177;&#8201;1.00</td><td>n.s.</td></tr><tr><td>Height (cm)</td><td>169.4&#8201;&#177;&#8201;0.53</td><td>168.8&#8201;&#177;&#8201;0.80</td><td>n.s.</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.5&#8201;&#177;&#8201;0.22</td><td>23.9&#8201;&#177;&#8201;0.27</td><td>n.s.</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.48&#8201;&#177;&#8201;0.07</td><td>1.56&#8201;&#177;&#8201;0.16</td><td>n.s.</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>82.2&#8201;&#177;&#8201;2.51</td><td>76.9&#8201;&#177;&#8201;3.02</td><td>n.s.</td></tr><tr><td>SBP (mmHg)</td><td>134.8&#8201;&#177;&#8201;1.12</td><td>139.5&#8201;&#177;&#8201;2.01</td><td>0.041</td></tr><tr><td>DBP (mmHg)</td><td>86.6&#8201;&#177;&#8201;0.78</td><td>89.3&#8201;&#177;&#8201;1.22</td><td>0.054</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.38&#8201;&#177;&#8201;0.09</td><td>1.63&#8201;&#177;&#8201;0.13</td><td>n.s.</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.4 (4&#8211;23)&#8201;&#177;&#8201;0.34</td><td>11.3 (4&#8211;21)&#8201;&#177;&#8201;0.58</td><td>n.s.</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.4 (4&#8211;19)&#8201;&#177;&#8201;0.24</td><td>8.6 (4&#8211;19)&#8201;&#177;&#8201;0.49</td><td>n.s.</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;4.77&#8201;&#177;&#8201;0.41</td><td>&#8722;6.82&#8201;&#177;&#8201;0.92</td><td>0.043</td></tr></tbody>
###xml 2180 3171 2103 3038 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th>C1797C (217)</th><th>1797T (111)</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>Mean (range) &#177; SEM</th><th>Mean (range) &#177; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.5 (16&#8211;77)&#8201;&#177;&#8201;0.95</td><td>31.6 (16&#8211;72)&#8201;&#177;&#8201;1.31</td><td>n.s.</td></tr><tr><td>Age at biopsy (years)</td><td>34.9 (16&#8211;77)&#8201;&#177;&#8201;0.99</td><td>34.4 (16&#8211;72)&#8201;&#177;&#8201;1.33</td><td>n.s.</td></tr><tr><td>Males (% men)</td><td>168 (77%)</td><td>79 (71%)</td><td>n.s.</td></tr><tr><td>Hypertensive (%)</td><td>99 (46%)</td><td>59 (53%)</td><td>n.s.</td></tr><tr><td>Antihypertensive treatment (%)</td><td>94 (43%)</td><td>58 (52%)</td><td>n.s.</td></tr><tr><td>Macrohematuria (%)</td><td>102 (47%)</td><td>41 (37%)</td><td>n.s.</td></tr><tr><td>Body weight (kg)</td><td>70.9&#8201;&#177;&#8201;0.72</td><td>68.9&#8201;&#177;&#8201;1.00</td><td>n.s.</td></tr><tr><td>Height (cm)</td><td>169.4&#8201;&#177;&#8201;0.53</td><td>168.8&#8201;&#177;&#8201;0.80</td><td>n.s.</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.5&#8201;&#177;&#8201;0.22</td><td>23.9&#8201;&#177;&#8201;0.27</td><td>n.s.</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.48&#8201;&#177;&#8201;0.07</td><td>1.56&#8201;&#177;&#8201;0.16</td><td>n.s.</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>82.2&#8201;&#177;&#8201;2.51</td><td>76.9&#8201;&#177;&#8201;3.02</td><td>n.s.</td></tr><tr><td>SBP (mmHg)</td><td>134.8&#8201;&#177;&#8201;1.12</td><td>139.5&#8201;&#177;&#8201;2.01</td><td>0.041</td></tr><tr><td>DBP (mmHg)</td><td>86.6&#8201;&#177;&#8201;0.78</td><td>89.3&#8201;&#177;&#8201;1.22</td><td>0.054</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.38&#8201;&#177;&#8201;0.09</td><td>1.63&#8201;&#177;&#8201;0.13</td><td>n.s.</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.4 (4&#8211;23)&#8201;&#177;&#8201;0.34</td><td>11.3 (4&#8211;21)&#8201;&#177;&#8201;0.58</td><td>n.s.</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.4 (4&#8211;19)&#8201;&#177;&#8201;0.24</td><td>8.6 (4&#8211;19)&#8201;&#177;&#8201;0.49</td><td>n.s.</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;4.77&#8201;&#177;&#8201;0.41</td><td>&#8722;6.82&#8201;&#177;&#8201;0.92</td><td>0.043</td></tr></tbody></table>
###xml 3171 3381 3038 3248 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="74">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p>
###xml 3381 3382 3248 3249 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3421 3423 3288 3290 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 3381 3424 3248 3291 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="75"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p>
###xml 3171 3424 3038 3291 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="74">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p textid="75"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot>
###xml 2072 3424 1998 3291 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="73">Baseline patient demographics, clinical and laboratory data according to ADD2 (&#946;-adducin) genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th>C1797C (217)</th><th>1797T (111)</th><th rowspan="2"><italic>p</italic></th></tr><tr><th>Mean (range) &#177; SEM</th><th>Mean (range) &#177; SEM</th></tr></thead><tbody><tr><td>Age at presentation (years)</td><td>31.5 (16&#8211;77)&#8201;&#177;&#8201;0.95</td><td>31.6 (16&#8211;72)&#8201;&#177;&#8201;1.31</td><td>n.s.</td></tr><tr><td>Age at biopsy (years)</td><td>34.9 (16&#8211;77)&#8201;&#177;&#8201;0.99</td><td>34.4 (16&#8211;72)&#8201;&#177;&#8201;1.33</td><td>n.s.</td></tr><tr><td>Males (% men)</td><td>168 (77%)</td><td>79 (71%)</td><td>n.s.</td></tr><tr><td>Hypertensive (%)</td><td>99 (46%)</td><td>59 (53%)</td><td>n.s.</td></tr><tr><td>Antihypertensive treatment (%)</td><td>94 (43%)</td><td>58 (52%)</td><td>n.s.</td></tr><tr><td>Macrohematuria (%)</td><td>102 (47%)</td><td>41 (37%)</td><td>n.s.</td></tr><tr><td>Body weight (kg)</td><td>70.9&#8201;&#177;&#8201;0.72</td><td>68.9&#8201;&#177;&#8201;1.00</td><td>n.s.</td></tr><tr><td>Height (cm)</td><td>169.4&#8201;&#177;&#8201;0.53</td><td>168.8&#8201;&#177;&#8201;0.80</td><td>n.s.</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.5&#8201;&#177;&#8201;0.22</td><td>23.9&#8201;&#177;&#8201;0.27</td><td>n.s.</td></tr><tr><td>Serum creatinine (mg/dl)</td><td>1.48&#8201;&#177;&#8201;0.07</td><td>1.56&#8201;&#177;&#8201;0.16</td><td>n.s.</td></tr><tr><td>Creatinine clearance (ml/min)<sup>a</sup></td><td>82.2&#8201;&#177;&#8201;2.51</td><td>76.9&#8201;&#177;&#8201;3.02</td><td>n.s.</td></tr><tr><td>SBP (mmHg)</td><td>134.8&#8201;&#177;&#8201;1.12</td><td>139.5&#8201;&#177;&#8201;2.01</td><td>0.041</td></tr><tr><td>DBP (mmHg)</td><td>86.6&#8201;&#177;&#8201;0.78</td><td>89.3&#8201;&#177;&#8201;1.22</td><td>0.054</td></tr><tr><td>Urinary protein excretion (g/24&#160;h)</td><td>1.38&#8201;&#177;&#8201;0.09</td><td>1.63&#8201;&#177;&#8201;0.13</td><td>n.s.</td></tr><tr><td>Follow-up from presentation (years)</td><td>11.4 (4&#8211;23)&#8201;&#177;&#8201;0.34</td><td>11.3 (4&#8211;21)&#8201;&#177;&#8201;0.58</td><td>n.s.</td></tr><tr><td>Follow-up from biopsy (years)</td><td>8.4 (4&#8211;19)&#8201;&#177;&#8201;0.24</td><td>8.6 (4&#8211;19)&#8201;&#177;&#8201;0.49</td><td>n.s.</td></tr><tr><td>Renal function loss (ml/min&#160;year)</td><td>&#8722;4.77&#8201;&#177;&#8201;0.41</td><td>&#8722;6.82&#8201;&#177;&#8201;0.92</td><td>0.043</td></tr></tbody></table><table-wrap-foot><p textid="74">If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis</p><p textid="75"><sup>a</sup>Computed with Cockcroft&#8211;Gault formula [<xref ref-type="bibr" rid="CR24">24</xref>]</p></table-wrap-foot></table-wrap>
###xml 734 741 <span type="species:ncbi:9606">patient</span>
###xml 1051 1054 <span type="species:ncbi:9606">men</span>
###xml 2088 2095 <span type="species:ncbi:9606">patient</span>
###xml 2401 2404 <span type="species:ncbi:9606">men</span>
The frequencies of ADD1 (alpha-adducin) and ADD2 (beta-adducin) genotypes are summarized in Table 2. Clinical characteristics according to ADD1 and ADD2 genotype are reported in Tables 3 and 4, respectively. Carriers of at least one ADD2 1797T allele had slightly higher blood pressure. The degree of renal function loss was affected by ADD2 (Table 4), but not by ADD1 genotypes (Table 3). Table 2Distribution of ADD1 (alpha-adducin) and ADD2 (beta-adducin) genotypesADD1ADD2Gly460Gly231 (70.4%)C1797C217 (66.2%)Gly460Trp85 (25.9%)C1797T95 (29.0%)Trp460Trp12 (3.7%)T1797T16 (4.9%)Genotype frequencies are in Hardy-Weinberg equilibrium (test for deviation from Hardy-Weinberg: p = 0.826 for ADD1 and p = 0.841 for ADD2)Table 3Baseline patient demographics, clinical and laboratory data according to ADD1 (alpha-adducin) genotypeVariableGly460Gly (231)460Trp (97)pMean (range) +/- SEMMean (range) +/- SEMAge at presentation (years)31.5 (16-77) +/- 0.9131.6 (15-72) +/- 1.42n.s.Age at biopsy (years)34.8 (16-77) +/- 0.9534.6 (17-72) +/- 1.43n.s.Males (% men)175 (76%)72 (74%)n.s.Hypertensive (%)144 (62%)44 (45%)n.s.Antihypertensive treatment (%)108 (47%)44 (45%)n.s.Macrohematuria (%)94 (41%)49 (50%)n.s.Body weight (kg)70.3 +/- 0.7170.1 +/- 1.02n.s.Height (cm)169.4 +/- 0.56168.8 +/- 0.76n.s.Body mass index (kg/m2)24.3 +/- 0.2024.5 +/- 0.32n.s.Serum creatinine (mg/dl)1.52 +/- 0.101.47 +/- 0.08n.s.Creatinine clearance (ml/min)a81.0 +/- 2.2479.0 +/- 3.90n.s.SBP (mmHg)135.8 +/- 1.20137.7 +/- 1.90n.s.DBP (mmHg)87.2 +/- 0.8088.5 +/- 1.22n.s.Urinary protein excretion (g/24 h)1.47 +/- 0.081.46 +/- 0.15n.s.Follow-up from presentation (years)11.3 (4-23) +/- 0.3511.4 (4-23) +/- 0.55n.s.Follow-up from biopsy (years)8.3 (4-19) +/- 0.308.7 (4-19) +/- 0.49n.s.Renal function loss (ml/min year)-5.04 +/- 0.42-6.46 +/- 1.00n.s.If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysisaComputed with Cockcroft-Gault formula [24]Table 4Baseline patient demographics, clinical and laboratory data according to ADD2 (beta-adducin) genotypeVariableC1797C (217)1797T (111)pMean (range) +/- SEMMean (range) +/- SEMAge at presentation (years)31.5 (16-77) +/- 0.9531.6 (16-72) +/- 1.31n.s.Age at biopsy (years)34.9 (16-77) +/- 0.9934.4 (16-72) +/- 1.33n.s.Males (% men)168 (77%)79 (71%)n.s.Hypertensive (%)99 (46%)59 (53%)n.s.Antihypertensive treatment (%)94 (43%)58 (52%)n.s.Macrohematuria (%)102 (47%)41 (37%)n.s.Body weight (kg)70.9 +/- 0.7268.9 +/- 1.00n.s.Height (cm)169.4 +/- 0.53168.8 +/- 0.80n.s.Body mass index (kg/m2)24.5 +/- 0.2223.9 +/- 0.27n.s.Serum creatinine (mg/dl)1.48 +/- 0.071.56 +/- 0.16n.s.Creatinine clearance (ml/min)a82.2 +/- 2.5176.9 +/- 3.02n.s.SBP (mmHg)134.8 +/- 1.12139.5 +/- 2.010.041DBP (mmHg)86.6 +/- 0.7889.3 +/- 1.220.054Urinary protein excretion (g/24 h)1.38 +/- 0.091.63 +/- 0.13n.s.Follow-up from presentation (years)11.4 (4-23) +/- 0.3411.3 (4-21) +/- 0.58n.s.Follow-up from biopsy (years)8.4 (4-19) +/- 0.248.6 (4-19) +/- 0.49n.s.Renal function loss (ml/min year)-4.77 +/- 0.41-6.82 +/- 0.920.043If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysisaComputed with Cockcroft-Gault formula [24]
###end p 67
###begin p 68
Distribution of ADD1 (alpha-adducin) and ADD2 (beta-adducin) genotypes
###end p 68
###begin p 69
###xml 96 97 96 97 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 119 120 119 120 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Genotype frequencies are in Hardy-Weinberg equilibrium (test for deviation from Hardy-Weinberg: p = 0.826 for ADD1 and p = 0.841 for ADD2)
###end p 69
###begin p 70
###xml 9 16 <span type="species:ncbi:9606">patient</span>
Baseline patient demographics, clinical and laboratory data according to ADD1 (alpha-adducin) genotype
###end p 70
###begin p 71
If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis
###end p 71
###begin p 72
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 40 42 40 42 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
aComputed with Cockcroft-Gault formula [24]
###end p 72
###begin p 73
###xml 9 16 <span type="species:ncbi:9606">patient</span>
Baseline patient demographics, clinical and laboratory data according to ADD2 (beta-adducin) genotype
###end p 73
###begin p 74
If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis
###end p 74
###begin p 75
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 40 42 40 42 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
aComputed with Cockcroft-Gault formula [24]
###end p 75
###begin p 76
###xml 112 113 112 113 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab5" ref-type="table">5</xref>
###xml 119 120 119 120 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 120 121 120 121 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 384 385 384 385 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 385 386 385 386 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 396 397 396 397 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 477 478 477 478 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 490 497 490 497 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;5</label>
###xml 497 622 497 615 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="77">ANOVA for statistical model used to test effects of interactions among ADD1 (&#945;-adducin) and ADD2 (&#946;-adducin) genotypes</p>
###xml 497 622 497 615 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="77">ANOVA for statistical model used to test effects of interactions among ADD1 (&#945;-adducin) and ADD2 (&#946;-adducin) genotypes</p></caption>
###xml 622 628 615 621 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Source</th>
###xml 628 632 621 622 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</th>
###xml 632 644 622 631 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">std err &#946;</th>
###xml 644 664 631 651 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">[95% Conf. Interval]</th>
###xml 664 665 651 652 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 664 671 651 658 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><italic>F</italic> value</th>
###xml 671 672 658 659 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 671 678 658 665 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 622 678 615 665 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>Source</th><th>&#946;</th><th>std err &#946;</th><th colspan="2">[95% Conf. Interval]</th><th><italic>F</italic> value</th><th><italic>p</italic> value</th></tr>
###xml 622 678 615 665 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Source</th><th>&#946;</th><th>std err &#946;</th><th colspan="2">[95% Conf. Interval]</th><th><italic>F</italic> value</th><th><italic>p</italic> value</th></tr></thead>
###xml 678 689 665 676 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Proteinuria</td>
###xml 689 694 676 681 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.24</td>
###xml 694 699 681 686 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.329</td>
###xml 699 705 686 692 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.892</td>
###xml 705 711 692 698 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;1.595</td>
###xml 711 716 698 703 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">43.36</td>
###xml 716 723 703 710 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 678 723 665 710 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Proteinuria</td><td char="." align="char">&#8722;2.24</td><td char="." align="char">0.329</td><td char="." align="char">&#8722;2.892</td><td char="." align="char">&#8722;1.595</td><td char="." align="char">43.36</td><td char="." align="char">&lt;0.0001</td></tr>
###xml 723 753 710 740 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Follow-up after biopsy (years)</td>
###xml 753 757 740 744 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.27</td>
###xml 757 762 744 749 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.098</td>
###xml 762 767 749 754 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.083</td>
###xml 767 772 754 759 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.471</td>
###xml 772 776 759 763 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.94</td>
###xml 776 782 763 769 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0052</td>
###xml 723 782 710 769 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Follow-up after biopsy (years)</td><td char="." align="char">0.27</td><td char="." align="char">0.098</td><td char="." align="char">0.083</td><td char="." align="char">0.471</td><td char="." align="char">7.94</td><td char="." align="char">0.0052</td></tr>
###xml 782 820 769 803 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#945;-Adducin (460Trp allele dominant)</td>
###xml 820 825 803 808 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.15</td>
###xml 825 830 808 813 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.091</td>
###xml 830 836 813 819 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;2.301</td>
###xml 836 841 819 824 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.994</td>
###xml 841 845 824 828 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.27</td>
###xml 845 851 828 834 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0397</td>
###xml 782 851 769 834 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#945;-Adducin (460Trp allele dominant)</td><td char="." align="char">&#8722;0.15</td><td char="." align="char">1.091</td><td char="." align="char">&#8722;2.301</td><td char="." align="char">1.994</td><td char="." align="char">4.27</td><td char="." align="char">0.0397</td></tr>
###xml 851 887 834 867 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-Adducin (1797T allele dominant)</td>
###xml 887 892 867 872 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;4.66</td>
###xml 892 897 872 877 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.490</td>
###xml 897 903 877 883 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;7.594</td>
###xml 903 909 883 889 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;1.728</td>
###xml 909 913 889 893 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8.28</td>
###xml 913 919 893 899 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0043</td>
###xml 851 919 834 899 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#946;-Adducin (1797T allele dominant)</td><td char="." align="char">&#8722;4.66</td><td char="." align="char">1.490</td><td char="." align="char">&#8722;7.594</td><td char="." align="char">&#8722;1.728</td><td char="." align="char">8.28</td><td char="." align="char">0.0043</td></tr>
###xml 919 938 899 918 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Adducin interaction</td>
###xml 938 942 918 922 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.45</td>
###xml 942 947 922 927 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.863</td>
###xml 947 952 927 932 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.787</td>
###xml 952 957 932 937 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8.117</td>
###xml 957 961 937 941 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.93</td>
###xml 961 967 941 947 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0092</td>
###xml 919 967 899 947 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Adducin interaction</td><td char="." align="char">4.45</td><td char="." align="char">1.863</td><td char="." align="char">0.787</td><td char="." align="char">8.117</td><td char="." align="char">4.93</td><td char="." align="char">0.0092</td></tr>
###xml 678 967 665 947 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Proteinuria</td><td char="." align="char">&#8722;2.24</td><td char="." align="char">0.329</td><td char="." align="char">&#8722;2.892</td><td char="." align="char">&#8722;1.595</td><td char="." align="char">43.36</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>Follow-up after biopsy (years)</td><td char="." align="char">0.27</td><td char="." align="char">0.098</td><td char="." align="char">0.083</td><td char="." align="char">0.471</td><td char="." align="char">7.94</td><td char="." align="char">0.0052</td></tr><tr><td>&#945;-Adducin (460Trp allele dominant)</td><td char="." align="char">&#8722;0.15</td><td char="." align="char">1.091</td><td char="." align="char">&#8722;2.301</td><td char="." align="char">1.994</td><td char="." align="char">4.27</td><td char="." align="char">0.0397</td></tr><tr><td>&#946;-Adducin (1797T allele dominant)</td><td char="." align="char">&#8722;4.66</td><td char="." align="char">1.490</td><td char="." align="char">&#8722;7.594</td><td char="." align="char">&#8722;1.728</td><td char="." align="char">8.28</td><td char="." align="char">0.0043</td></tr><tr><td>Adducin interaction</td><td char="." align="char">4.45</td><td char="." align="char">1.863</td><td char="." align="char">0.787</td><td char="." align="char">8.117</td><td char="." align="char">4.93</td><td char="." align="char">0.0092</td></tr></tbody>
###xml 622 967 615 947 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Source</th><th>&#946;</th><th>std err &#946;</th><th colspan="2">[95% Conf. Interval]</th><th><italic>F</italic> value</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Proteinuria</td><td char="." align="char">&#8722;2.24</td><td char="." align="char">0.329</td><td char="." align="char">&#8722;2.892</td><td char="." align="char">&#8722;1.595</td><td char="." align="char">43.36</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>Follow-up after biopsy (years)</td><td char="." align="char">0.27</td><td char="." align="char">0.098</td><td char="." align="char">0.083</td><td char="." align="char">0.471</td><td char="." align="char">7.94</td><td char="." align="char">0.0052</td></tr><tr><td>&#945;-Adducin (460Trp allele dominant)</td><td char="." align="char">&#8722;0.15</td><td char="." align="char">1.091</td><td char="." align="char">&#8722;2.301</td><td char="." align="char">1.994</td><td char="." align="char">4.27</td><td char="." align="char">0.0397</td></tr><tr><td>&#946;-Adducin (1797T allele dominant)</td><td char="." align="char">&#8722;4.66</td><td char="." align="char">1.490</td><td char="." align="char">&#8722;7.594</td><td char="." align="char">&#8722;1.728</td><td char="." align="char">8.28</td><td char="." align="char">0.0043</td></tr><tr><td>Adducin interaction</td><td char="." align="char">4.45</td><td char="." align="char">1.863</td><td char="." align="char">0.787</td><td char="." align="char">8.117</td><td char="." align="char">4.93</td><td char="." align="char">0.0092</td></tr></tbody></table>
###xml 967 1010 947 990 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="78">Dependent variable: eGFR loss (ml/min&#160;year)</p>
###xml 967 1010 947 990 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="78">Dependent variable: eGFR loss (ml/min&#160;year)</p></table-wrap-foot>
###xml 490 1010 490 990 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab5"><label>Table&#160;5</label><caption><p textid="77">ANOVA for statistical model used to test effects of interactions among ADD1 (&#945;-adducin) and ADD2 (&#946;-adducin) genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Source</th><th>&#946;</th><th>std err &#946;</th><th colspan="2">[95% Conf. Interval]</th><th><italic>F</italic> value</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Proteinuria</td><td char="." align="char">&#8722;2.24</td><td char="." align="char">0.329</td><td char="." align="char">&#8722;2.892</td><td char="." align="char">&#8722;1.595</td><td char="." align="char">43.36</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>Follow-up after biopsy (years)</td><td char="." align="char">0.27</td><td char="." align="char">0.098</td><td char="." align="char">0.083</td><td char="." align="char">0.471</td><td char="." align="char">7.94</td><td char="." align="char">0.0052</td></tr><tr><td>&#945;-Adducin (460Trp allele dominant)</td><td char="." align="char">&#8722;0.15</td><td char="." align="char">1.091</td><td char="." align="char">&#8722;2.301</td><td char="." align="char">1.994</td><td char="." align="char">4.27</td><td char="." align="char">0.0397</td></tr><tr><td>&#946;-Adducin (1797T allele dominant)</td><td char="." align="char">&#8722;4.66</td><td char="." align="char">1.490</td><td char="." align="char">&#8722;7.594</td><td char="." align="char">&#8722;1.728</td><td char="." align="char">8.28</td><td char="." align="char">0.0043</td></tr><tr><td>Adducin interaction</td><td char="." align="char">4.45</td><td char="." align="char">1.863</td><td char="." align="char">0.787</td><td char="." align="char">8.117</td><td char="." align="char">4.93</td><td char="." align="char">0.0092</td></tr></tbody></table><table-wrap-foot><p textid="78">Dependent variable: eGFR loss (ml/min&#160;year)</p></table-wrap-foot></table-wrap>
The ANOVA table for the model, considering ADD1 460Trp allele and ADD2 1797T allele dominant, is shown in Table 5. The R2 for the model, including the effect of urinary protein excretion at diagnosis, was 0.245. When only ADD1 and ADD2 genotypes and their interaction were included, the model remained statistically significant, though the variance explained was substantially lower (R2 = 0.057, p = 0.0004). Note that also ADD1-ADD2 interaction was statistically significant (p = 0.0174). Table 5ANOVA for statistical model used to test effects of interactions among ADD1 (alpha-adducin) and ADD2 (beta-adducin) genotypesSourcebetastd err beta[95% Conf. Interval]F valuep valueProteinuria-2.240.329-2.892-1.59543.36<0.0001Follow-up after biopsy (years)0.270.0980.0830.4717.940.0052alpha-Adducin (460Trp allele dominant)-0.151.091-2.3011.9944.270.0397beta-Adducin (1797T allele dominant)-4.661.490-7.594-1.7288.280.0043Adducin interaction4.451.8630.7878.1174.930.0092Dependent variable: eGFR loss (ml/min year)
###end p 76
###begin p 77
ANOVA for statistical model used to test effects of interactions among ADD1 (alpha-adducin) and ADD2 (beta-adducin) genotypes
###end p 77
###begin p 78
Dependent variable: eGFR loss (ml/min year)
###end p 78
###begin p 79
###xml 230 231 226 227 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 293 294 285 286 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 463 464 451 452 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 528 529 512 513 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Neither ADD1 nor ADD2 was associated to proteinuria. However, only in carriers of the adducin mutant alleles, ACE inhibitors significantly decreased the level of proteinuria (ADD1 460Trp 1.87 +/- 0.24 versus 1.18 +/- 0.17 g/24 h, p = 0.02; ADD2 1797T 1.96 +/- 0.2 versus 1.14 +/- 0.17 g/24 h, p = 0.04). Conversely, in carriers of the adducin wild-type alleles, ACE inhibitors did not affect proteinuria (ADD1 Gly460Gly 1.63 +/- 0.12 versus 1.38 +/- 0.11 g/24 h, p = 0.15; ADD2 C1797C 1.56 +/- 0.13 versus 1.28 +/- 0.11 g/24 h, p = 0.13).
###end p 79
###begin p 80
###xml 491 493 489 491 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 498 500 496 498 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 609 611 605 607 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 616 618 612 614 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 620 621 616 617 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 803 805 797 799 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 810 812 804 806 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 851 853 843 845 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 858 860 850 852 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
To provide more information on the relationships between GFR loss per year, genotypes, and level of proteinuria at onset, these variables were analyzed with an additional linear model in which the degree of proteinuria was analyzed as tertiles, and least square means were obtained for the rate of renal function loss in each of these classes. The rate of renal function decline was more than double in carriers of the ADD1 460Trp + ADD2 1797T combination of genotypes (-4.04 +/- 1.15 ml min-1 year-1 per gram of urinary protein) than in carriers of the ADD1 Gly460Gly + ADD2 C1797C one (-1.64 +/- 0.36 ml min-1 year-1; p = 0.005), with intermediate and similar values for the combinations where only one mutant adducin (either ADD1 or ADD2) genotype was present (Gly460Gly + 1797T -3.04 +/- 0.57 ml min-1 year-1; 460Trp + C1797C -3.09 +/- 0.44 ml min-1 year-1).
###end p 80
###begin p 81
###xml 0 86 0 79 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Glomerular immunohistochemical analysis for &#945;- and &#946;-adducin in IgA nephropathy</bold>
###xml 531 533 517 519 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="MOESM1" ref-type="">10</xref>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
Glomerular immunohistochemical analysis for alpha- and beta-adducin in IgA nephropathy Twenty IgAN patients, chosen for the availability of the material for immunohistochemistry, have been analyzed and divided into two groups according to the rate of renal function decline: stable renal function (nonprogressors) or rapidly progressing toward end-stage renal failure (progressors). We did not find any difference in alpha- and beta-adducin staining. The results of two representative patients are shown in the supplementary Fig. S10.
###end p 81
###begin title 82
Discussion
###end title 82
###begin p 83
###xml 617 619 597 599 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 134 138 <span type="species:ncbi:10116">rats</span>
###xml 144 150 <span type="species:ncbi:9606">humans</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10116">rats</span>
###xml 713 717 <span type="species:ncbi:10116">rats</span>
###xml 1000 1004 <span type="species:ncbi:10116">rats</span>
###xml 1245 1250 <span type="species:ncbi:9606">human</span>
The major findings described in the present work are (1) the localization of alpha- and beta-adducin in glomerular podocytes in mice, rats, and humans; (2) in beta-adducin null mice, compared to wild-type controls, carrying the same polymorphic beta-adducin variant (Q529R) as MHS rats, the expression of proteins of podocyte slit membrane or foot process cytoskeleton (such as phospho-nephrin, synaptopodin, alpha-actinin, ZO-1, Fyn) is increased, while the urinary protein excretion was decreased. Therefore, the absence of beta-adducin reduced the glomerular permeability to proteins. In contrast to erythrocytes [20], beta-adducin deletion did not induce a loss of alpha-adducin in glomeruli. (3) In congenic rats, the decreased expression of key podocyte proteins (such as nephrin, synaptopodin, alpha-actinin, ZO-1, podocin, Fyn), followed by an increase of urinary protein excretion and glomerular damage, traveled together with the DNA segment containing the beta-adducin polymorphism of MHS rats. This effect was blunted by the simultaneous presence of MHS alpha-adducin. The epistatic interaction between alpha- and beta-adducin suggests that the glomerular changes observed here were very likely due to the adducin variations. (4) In human IgAN, the rate of renal function decline increased when a specific combination of alpha- and beta-adducin polymorphisms was present. Taken together, these observations strongly support the notion that alphabeta-adducin heterodimers are involved in the molecular mechanisms underlying the process of glomerular permeability, associated with an increase of protein excretion and progression rate of glomerular failure.
###end p 83
###begin p 84
###xml 511 513 508 510 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 991 993 988 990 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 290 295 <span type="species:ncbi:9606">human</span>
###xml 323 328 <span type="species:ncbi:9606">human</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
###xml 775 780 <span type="species:ncbi:9606">human</span>
###xml 1072 1078 <span type="species:ncbi:9606">humans</span>
###xml 1218 1224 <span type="species:ncbi:9606">humans</span>
In human IgAN, beta-adducin polymorphism was associated to renal function decline, but not to the average urinary protein excretion, at least during the first 2 years after diagnosis. It is not clear whether this discrepancy with the rodent findings is real or due to the complexity of the human condition. In fact, in the human study, 47% of patients were on ACEI or other antihypertensive treatment. Renin-angiotensin system inhibition may differently affect proteinuria and progression toward renal failure [32] and may also differ across genotypes. In fact, the reduction of proteinuria associated to ACEI treatment was significant only in carriers of mutant ADD1 460Trp or ADD2 1797T alleles. It is worth mentioning that the cell surface expression of ACE is greater in human cultured fibroblasts carrying the ADD1 Trp allele, or in renal cells transfected with the ADD1 Trp allele, than in fibroblasts carrying the ADD1 Gly allele, or renal cells transfected with the ADD1 Gly allele [33]. These observations, taken together with the larger genetic heterogeneity of humans as compared to that of inbred strains of rodents and the difference in the adducin mutation sites, may account for the discrepancy between humans and rodents on the genotype-proteinuria relationship.
###end p 84
###begin p 85
###xml 71 73 71 73 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 234 236 234 236 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 237 239 237 239 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 339 341 339 341 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 488 490 488 490 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 696 697 696 697 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 699 700 699 700 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 702 704 702 704 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
Nephrin is an essential component of the glomerular podocyte junction [34] and participates to the formation of the glomerular filtration barrier via interactions with associated proteins, including the Src family protein kinase Fyn [34-36]. Engagement of the nephrin ectodomain induces Fyn activation that favors nephrin phosphorylation [35] and the recruitment of adaptor proteins, such as Nck, involved in the regulation of podocyte junction formation and actin cytoskeletal dynamics [36]. Mutations of several podocyte proteins, or the knockout of Fyn or nephrin in mice, induce a rearrangement of the actin cytoskeleton and the disruption of the filtration barrier leading to renal disease [3, 4, 36].
###end p 85
###begin p 86
###xml 75 77 72 74 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 128 131 122 125 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">489</sup>
###xml 171 172 165 166 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 222 224 216 218 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 380 383 371 374 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">489</sup>
###xml 285 288 <span type="species:ncbi:10116">rat</span>
Recently, also beta-adducin has been shown to be a specific target of Fyn [37]. Fyn binds and phosphorylates beta-adducin at Tyr489, permitting its association with Fyn-SH2 domain and translocation to the plasma membrane [37]. Interestingly, the polymorphism (Q529R) identified in the rat beta-adducin C-terminal domain maps close to the Fyn-dependent phosphorylation residue (Tyr489).
###end p 86
###begin p 87
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 63 67 <span type="species:ncbi:10116">rats</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 526 529 <span type="species:ncbi:10116">rat</span>
The data presented here in beta-adducin null mice and congenic rats support the hypothesis that beta-adducin may induce a reduction of Fyn protein expression on the cell membrane resulting in a downregulation of phosphorylated nephrin and related podocyte proteins, such as synaptopodin, ZO-1, and alpha-actinin, associated with the appearance of glomerular podocyte damage and proteinuria. Conversely, the knockout of the beta-adducin gene in mice, or the presence of the polymorphic alpha-adducin variant in MHS, NA, or NAB rat substrains, seems to be protective. This effect appears to occur through the reactivation of the nephrin signaling pathway.
###end p 87
###begin p 88
###xml 0 11 0 11 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Limitations</bold>
###xml 1109 1111 1109 1111 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1546 1547 1532 1533 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 536 543 <span type="species:ncbi:9606">patient</span>
###xml 873 877 <span type="species:ncbi:10090">mice</span>
###xml 958 961 <span type="species:ncbi:10116">rat</span>
###xml 1015 1021 <span type="species:ncbi:9606">humans</span>
Limitations As a first point, with regards to the human studies, one should keep in mind that we used the Cockcroft-Gault formula to estimate the glomerular filtration rate. Though a suboptimal indicator, this formula is of practical use because it provides a quantitative estimate of the milliliters per minute loss of renal function in relation to the variables considered. Another note of caution concerns serum creatinine assay. Although creatinine had not been assayed by a unique unit, we respected center consistency, since each patient referred to his/her referring center that was using the same intracenter standards. A number of questions remain, however, unanswered. We have attempted to ascertain an association between a variety of genetic manipulations of adducin and the glomerular phenotypes. These include precise gene manipulations, like the knockout in mice, the introgression of DNA segments containing the adducin loci from one inbreed rat strain to another and genetic association studies in humans. Certainly, the introgression of a DNA segment, harboring other genes besides adducin [21], cannot exclude their influence on our findings. However, this weakness is tempered by the interaction between alpha- and beta-adducin DNA segments. In fact, the possibility that the other genes, mapping in close vicinity to the adducin locus in the DNA fragment, display such an interaction on the phenotypes we have measured is unlikely in view of the biochemical requirement that alpha- and beta-adducin function as heterodimers [6] and that both subunits are present in podocytes.
###end p 88
###begin p 89
###xml 717 719 717 719 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 538 542 <span type="species:ncbi:10116">rats</span>
###xml 547 553 <span type="species:ncbi:9606">humans</span>
###xml 686 689 <span type="species:ncbi:10116">rat</span>
###xml 694 699 <span type="species:ncbi:9606">human</span>
As in all the other studies aimed at establishing a putative relationship between a given gene variation and complex phenotypes, like progression of renal failure or proteinuria, when we change the context, we increase the number of confounding factors (such as variations in the genetic and environmental backgrounds) that may differently modulate the effect of the gene variants of interest. Therefore, we may anticipate some differences in the phenotype effect. Moreover, in our case, adducin mutations occur at different positions in rats and humans. In spite of the very high identity between the adducin of the two species (92%) and the many protein function similarities between rat and human mutant variants [10], the difference in the mutation site may produce protein function variations that may differ across species.
###end p 89
###begin p 90
###xml 0 11 0 11 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Conclusions</bold>
Conclusions Genetic studies involve two major steps: (1) to demonstrate that a given gene is involved in the regulation of a phenotype and leads to disease (in our case, adducin and glomerular permeability) and (2) to define the mechanistic steps linking these gene variations to the clinical phenotypes. While we believe we have provided solid data to support the first step, the second one will require further investigation to explore the mechanism underlying the reduction of podocyte proteins that, in turn, affects the glomerular permeability to proteins.
###end p 90
###begin p 91
###xml 245 252 <span type="species:ncbi:9606">patient</span>
The wide range of contexts explored here strengthens the conclusion that alpha- and beta-adducins are involved in glomerular disease. We may speculate that the magnitude of the adducin polymorphism impact on glomerular disease of the individual patient may be modest, or more severe, according to the individual genetic-environmental background. Certainly, adducin genetic variants seem to exert a modifier rather than a triggering role within the heterogeneous network of the other podocyte gene polymorphisms.
###end p 91
###begin title 92
Electronic supplementary materials
###end title 92
###begin p 93
Below is the link to the electronic supplementary material. 
###end p 93
###begin p 94
ESMpdf1 (PDF 5222 kb)
###end p 94
###begin title 95
Acknowledgment
###end title 95
###begin p 96
We thank Prof. D. Kerjaschki, Department of Pathology, Medical University of Vienna, for help in immunogold electron microscopy and Dr A. Corbelli for electron microscopy studies. The authors (MF, IM, CC, FP, FP) are Prassis sigma-tau employees and (GB) is a Prassis sigma-tau consultant.
###end p 96
###begin p 97
###xml 0 8 0 8 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fundings</bold>
Fundings This study was supported in part by a grant from the Telethon Foundation EC 861, FIRB2003 research grant RBLA038RMA-010 from the Italian Ministry of University and Scientific Research, by Ingenious Hypercare LSHM-CT-2006-037093 (DC), by HYPERGENES grant HEALTH-F4-2007-201550 (DC), and by National Institutes of Health, grant 1 R01 HL075714 (LLP).
###end p 97
###begin p 98
###xml 0 11 0 11 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 98
###begin title 99
References
###end title 99
###begin article-title 100
The spectrum of podocytopathies: a unifying view of glomerular disease
###end article-title 100
###begin article-title 101
Nephrin and related proteins in the pathogenesis of nephropathy
###end article-title 101
###begin article-title 102
Podocyte-specific gene mutations are coming of age
###end article-title 102
###begin article-title 103
Specific podocin mutations correlate with age of onset in steroid-resistant nephrotic syndrome
###end article-title 103
###begin article-title 104
Are podocytes passive or provocative in proteinuric glomerular pathology?
###end article-title 104
###begin article-title 105
Adducin: structure, function and regulation
###end article-title 105
###begin article-title 106
Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport
###end article-title 106
###begin article-title 107
Two point mutations within the adducin genes are involved in blood pressure variation
###end article-title 107
###begin article-title 108
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension
###end article-title 108
###begin article-title 109
Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms
###end article-title 109
###begin article-title 110
Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation
###end article-title 110
###begin article-title 111
Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population
###end article-title 111
###begin article-title 112
Renal function in relation to three candidate genes
###end article-title 112
###begin article-title 113
Role of the alpha-adducin genotype on renal disease progression
###end article-title 113
###begin article-title 114
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Interaction between ACE and ADD1 gene polymorphisms in the progression of IgA nephropathy in Japanese patients
###end article-title 114
###begin article-title 115
Alpha-adducin Gly460Trp polymorphism and renal hemodynamics in essential hypertension
###end article-title 115
###begin article-title 116
Influence of the alpha-adducin and ACE gene polymorphism on the progression of autosomal-dominant polycystic kidney disease
###end article-title 116
###begin article-title 117
The commonest glomerulonephritis in the world: IgA nephropathy
###end article-title 117
###begin article-title 118
Validation of the Toronto formula to predict progression in IgA nephropathy
###end article-title 118
###begin article-title 119
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Targeted disruption of the beta adducin gene (Add2) causes red blood cell spherocytosis in mice
###end article-title 119
###begin article-title 120
###xml 87 91 <span type="species:ncbi:10116">rats</span>
Effect of Add1 gene transfer on blood pressure in reciprocal congenic strains of Milan rats
###end article-title 120
###begin article-title 121
Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis
###end article-title 121
###begin article-title 122
Predicting progression in IgA nephropathy
###end article-title 122
###begin article-title 123
Prediction of creatinine clearance from serum creatinine
###end article-title 123
###begin article-title 124
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Typical and atypical natural history of IgA nephropathy in adult patients
###end article-title 124
###begin article-title 125
IgA nephropathy: morphologic predictors of progressive renal disease
###end article-title 125
###begin article-title 126
Association between hypertension and variation in the alpha- and beta-adducin genes in a white population
###end article-title 126
###begin article-title 127
###xml 62 66 <span type="species:ncbi:10116">rats</span>
###xml 111 115 <span type="species:ncbi:10116">rats</span>
Age-dependent glomerulosclerosis and proteinuria occurring in rats of the Milan normotensive strain and not in rats of the Milan hypertensive strain
###end article-title 127
###begin article-title 128
###xml 69 73 <span type="species:ncbi:10116">rats</span>
Glomerular barrier dysfunction in glomerulosclerosis-resistant Milan rats with experimental diabetes: the role of renal haemodynamics
###end article-title 128
###begin article-title 129
###xml 85 89 <span type="species:ncbi:10116">rats</span>
Glomerular prostaglandins and thromboxane synthesis in normotensive and hypertensive rats of the Milan strain before and after development of hypertension
###end article-title 129
###begin article-title 130
###xml 55 61 <span type="species:ncbi:9606">people</span>
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial
###end article-title 130
###begin article-title 131
Angiotensin-converting enzyme I/D and alpha-adducin Gly460Trp polymorphisms: from angiotensin-converting enzyme activity to cardiovascular outcome
###end article-title 131
###begin article-title 132
Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton
###end article-title 132
###begin article-title 133
Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization
###end article-title 133
###begin article-title 134
Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes
###end article-title 134
###begin article-title 135
Fyn-induced phosphorylation of beta-adducin at tyrosine 489 and its role in their subcellular localization
###end article-title 135
###begin p 136
Mara Ferrandi and Daniele Cusi contributed equally to this study.
###end p 136

